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Theoretical studies on combined mIBG/TBI therapy of
neuroblastoma micrometastases
J.A. O'Donoghue, T.E. Wheldon, A. Barrett, J.W. Babich,
J. Moyes & S. Meller
Beatson Oncology Centre, Belvidere Hospital, Glasgow
G31 4PG; and The Royal Marsden Hospital, Sutton,
Surrey SM2 5PT, UK.
Measurements of M125IBG uptake in surgically excised
samples of neuroblastoma from 6 patients were used to
assess absorbed dose to micrometastases. Doses to achieve a
50% probability of cure were calculated using a simple
analysis. Two categories were examined: (a) absorbed dose
greater than 50% cure dose; (b) absorbed dose less than
50% cure dose. The number of patients falling into each
category depends on the tumour size and on the radionuclide
half-life in the tumour. For a 1 mm diameter tumour the
number of category (a) patients increases from 0 (t1/2 = 1.2
days) to 4 (t1/2=8 days). MIBG is less effective for smaller
tumours due to the reduced absorption of the beta-energy
from 1311. For a 0.2mm diameter tumour the number of
category (a) patients increases from 0 (t1/2=1.2 days) to 2
01/2=8 days). The use of mIBG in combination with total
body irradiation (TBI) and autologous bone marrow rescue
was investigated. For a 1 mm tumour the number in category
(a) increases from 3 (t1/2= 1.2 days) to 5 (t1/2=8 days). For a
0.2mm tumour all 6 patients remain in category (a) for the
full range of tumour half-times considered. Tumour doses
with combined mIBG/TBI are significantly higher than
achievable with either modality alone. Additionally, the two
modalities complement each other as TBI is relatively more
effective at eliminating small (<1 mm) micrometastases and
single cells whereas in mIBG is better for larger (>, 1mm)
micrometastases.
Radioimmunoimaging and CT in malignant melanoma
A.T. Elliott, R.M. MacKie, T. Murray, V.R. Doherty,
G. Gillen & F.G. Adams
Depts of Clinical Physics, Dermatology and Radiology,
Western Infirmary, Glasgow Gil 6NT, UK.
A monoclonal antibody raised against the high molecular
weight melanoma antigen was labelled with indium-111 and
injected intravenously into 25 patients with malignant mela-
noma. The results obtained from images at 24 and 96 hours
post i.v. administration of the antibody were compared with
results obtained from computerised tomography studies with
regard to detection of previously unrecognised sites of
metastatic disease and apparent false positive localisation.
Detailed study of the patients' clinical condition and detec-
tion rates using the two methods suggests that both methods
detect approximately 80% of clinically and pathologically
confirmed metastases. Of 62 known metastases, the antibody
detected 60 (81%), with 17 false positive results. False
negatives were most common in the lung. In 8 patients the
two methods were considered of equal value, in 10 the
monoclonal gave a greater amount of clinically relevant
information, and in 7 the CT was superior. In three patients
clinically significant metastatic lesions were detected by the
radiolabelled monoclonal which had not been previously
recognised either by CT scanning or on clinical grounds.
No patients had any adverse reaction to the antibody and
in the course of our study the dose of antibody was reduced
from 20mg to 200mg with no apparent loss of sensitivity. In
at least 2 patients uptake of the labelled monoclonal into
tumour sites would have been adequate for effective targeted
radiotherapy.
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The interaction of cellular factors with the NCR of HPV16
G.J. Sibbet & M.S. Campo
Beatson Institute, Glasgow, UK.
The progression of human papillomavirus 16 associated
cervical intraepithelial neoplasia (CIN) to cancer is fre-
quently accompanied by chromosomal integration of the
viral genome. The cell line SiHa, derived from a cervical
squamous cell carcinoma, contains a single integrated copy
of HPV16.
We have mapped a complex pattern of nuclease hyper-
sensitive sites (HSS), covering -500bp, at high resolution in
SiHa chromatin to the tissue specific enhancer within the
HPV16 non coding region (NCR). DNase footprinting (FP)
of cloned DNA in vitro confirms the presence of cellular
transacting factors (CTAFs) in SiHa nuclear extract with
binding specificity for at least 13 sites in the HPV16
enhancer. The majority of FPs contain the consensus
T/AGGCT/A, which is analogous to both the specific cyto-
keratin and ubiquitous CCAAT box motifs. However, the
bound CTAFs found in nuclear extracts of SiHa as well as
CaSki and HeLa are also found in non-epithelial K562 and
MRC5 cells and appear to be related to the CCAAT box
binding C/EBP but not to NFI/CTF, NFY or NFY*/CRF.
One of the nuclear HSS in the HPV16 enhancer in SiHa
contains overlapping DNA motif binding sites for API,
C/EBP and glucocorticoid receptor (GR).
We are currently determining how these factors compete
for their overlapping binding sites and how this effects the
regulation of HPV16 in SiHa and cervical neoplasia.
This work was funded by the Cancer Research Campaign.
The Harvey ras gene is activated in
papillomavirus-associated carcinomas of the upper
alimentary canal in cattle
M.S. Campo, I. Doherty, R. McCaffery, L.W. Coggins &
I.M. Kennedy
The Beatson Institute for Cancer Research, Garscube Estate,
Switchback Road, Bearsden, Glasgow G61 IBD, UK; and
The Institute of Virology, The University of Glasgow,
Church Street, Glasgow G12, UK.
The possible activation of ras sequences in papillomavirus-
associated carcinomas of the upper alimentary canal of cattle
was investigated by restriction enzyme and hybridisation
analysis, and by DNA-mediated transformation of NIH 3T3
cells. The DNA from three cancers, two squamous cell
carcinomas of the palate and the rumen, and one transitional
cell carcinoma of the urinary bladder, showed anomalous
restriction patterns for the c-Ha-ras sequences, indicating
rearrangements and, in the case of the palate cancer, amplifi-
cation. Cancer DNA was capable of inducing focus forma-
tion in the NIH 3T3 test. DNA from primary transformants
was used in a second round of transformation and secondary
transformants were analysed. Bovine Ha-ras sequences were
detected in all transformants. In addition, high levels of ras
transcripts were observed in several cancers. It is concluded
that the Ha-ras gene is activated in alimentary canal carci-
nomas and the possible relationship between papillomavirus
infection and activation of the ras gene is discussed.
This research was funded by the Cancer Research
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The presence and expression of human papillomavirus DNA
in oral squamous cell carcinoma
W.A. Yeudall, D.G. MacDonald, R. Smith, D.S. Soutar &
M.S. Campo
Beatson Institute for Cancer Research, Glasgow Dental
Hospital; and Canniesburn Hospital, Glasgow, UK.
Nineteen tumour samples from patients with intraoral squa-
mous cell carcinoma were screened for the presence of
human papillomavirus (HPV) DNA by Southern blot hybridi-
sation. Three of these (15.8%) were found to be positive, one
each containing HPV-4, HPV-16 and HPV-18. Adjacent
normal mucosa contained no or undetectable amounts of
viral sequences. Normal buccal mucosa from 25 cancer-free
individuals did not contain HPV DNA. In addition, all three
viral genomes were expressed in the respective lesions,
including the late genes, as detected by dot blot hybridi-
sation. This is the first report of HPV-4 associated with an
intraoral malignancy, and also the first report of expression
of papillomavirus sequences in oral tumours.
This research was funded by the Cancer Research
Campaign and the Medical Research Council.
Co-operation of bovine papillomavirus type 4 and activated
ras oncogene on the transformation of early passage bovine
fibroblasts in vitro
R. Jaggar & M.S. Campo
Beatson Institute, Glasgow, UK.
Early passage bovine fibroblasts derived from fetal palate
were transfected by electroporation with bovine papillo-
mavirus type 4 (BPV4) molecularly cloned at 2 different
restriction sites (BamHl and Sstl:the BPV4 cloned at the
BamH1 site interrupts the El ORF, while the Sstl clone
leaves the viral promoter and the entire early region intact),
the activated human Ha-ras oncogene (pT24), an avian
retroviral myc gene (pSVvmyc), and combinations of these
clones. After transfection, cells were grown to confluence
and maintained for up to 12 weeks. Foci of densely growing
cells appeared only in three cases - the combinations of:
ras+myc, ras+BPV4 Bl and ras+BPV4 Sstl. No foci were
obtained when cotransfecting BPV4 and the viral myc gene.
Foci were picked, generating cell lines which grew rapidly,
piled up and showed higher confluent density than control
monolayers. We are examining the tumorigenic character-
istics of these lines. BPV4 thus displays similar trans-
formation properties to various oncogenic human papillo-
maviruses.
This research was funded by the Cancer Research
Campaign and the Medical Research Council.
Initial characterisation of an in vitro inhibitor of
haematopoietic stem cell proliferation
G.J. Graham, E. Wright, M. Freshney, N.M. Wilkie &
I.B. Pragnell
Beatson Institute for Cancer Research, Glasgow G61 IBD
and MRC Radiobiology, Didcot OXJJ ORD, UK.
Considerable experimental evidence suggests the existence of
soluble, local activities regulating the proliferation of the
primitive haematopoietic stem cell (CFU-S). Two such activi-
ties have been described: a stimulator, which moves the
normally quiescent stem cells into the cell cycle, and an
inhibitor which triggers the stem cells out of cycle. These
activities are proteinaceous in nature and appear to be
products of distinct macrophage sub-populations. Both
activities appear to be specific for the stem cell and show no
activity on the more mature progenitor population. It has
been shown that crude inhibitory material has the ability to
protect the haematopoietic stem cell from cytotoxic drug
treatment in vivo. In view of the clinical potential for this
material in cancer treatment, purification and character-
isation of this regulator is of considerable importance.
To date, attempts at purifying such activities have been
hampered by all the problems common to the isolation of
biological molecules from in vivo sources. We have recently
detected an inhibitor-like activity from the 20-fold concent-
rated conditioned medium from J774.2 cells (a mouse macro-
phage cell line). This inhibitor preparation is active in
removing primitive haematopoietic stem cells (CFU-S) from
the cell cycle and is also active in inhibiting the development
of macroscopic CFU-A colonies which are believed to be an
in vitro equivalent of the CFU-S. As for the in vivo inhibitor,
the in vitro equivalent has no effect on progenitor cells and
appears therefore to be stem cell specific.
The above data will be discussed in more depth and
results relating to the initial biochemical characterisation of
the inhibitory activity will be presented. This study was
supported by the Cancer Research Campaign.
t(14;18) Studies in follicular lymphoma(FL) with Bcl-2, JH
and DH region oligonucleotides
F.E. Cotter, A. Tuszynski, C. Price, T.A. Lister,
A.M.Z. Rohatiner & B.D. Young
ICRF Department of Medical Oncology, St Bartholomew's
Hospital, London ECIA 7BE, UK.
Lymph node DNA from seventeen patients with FL was
studied by the polymerase chain reaction using synthesised
oligonucleotides with sequences corresponding to the Bcl-2
gene on chromosome 18, the immunoglobulin heavy chain
(JH) gene and diversity (DH) region on chromosome 14.
Reactions using Taq polymerase were carried out. The Bcl-2-
JH junction sequence was present in 7 cases by gel electro-
phoresis, blotting of the amplified fragment and probing
with radioactive labelled Bcl-2 probe. Reactions to amplify
the reciprocal junction region of the t(14;18) translocation
were carried out with a D (+) region and a Bcl-2 (-) primer
on the same samples. Reciprocal DH-Bcl-2 junctions were
detected in 6 samples, 4 of which had previously shown Bcl-
2-JH junctions. Dilutions of the DNA were made and
detection of amplification was possible to a dilution of 105.
DNA from complete remission bone marrows (BM) for 3 of
the 9 positive patients were studied pre and post in vitro
treatment with B1 antibody and complement for autologous
bone marrow transplantation. One demonstrated positive
amplification with JH region primers in the untreated BM
but none in the post treatment BM with JH or DH region
primers. In conclusion, detection of the t(14;18) translocation
appears to be maximised using both sets of primers.
Human c-myc oncogene protein in activated lymphocytes and
cell lines
D.G. Spiller, A.F. Chapman, D.M. Tidd &
H.M. Warenius
CRC Department of Radiation Oncology, University of
Liverpool, Clatterbridge Hospital, Wirral L64 4JY, UK.
It has been reported by a number of authors that c-myc
protein levels rise in lymphocytes within 3 to 5 hours ofTHIRTIETH BACR AND FOURTH ACP MEETINGS 481
treatment with phytohaemagglutinin (PHA), and that anti-
sense myc oligonucleotides can block this rise. We have
investigated this system in order to determine the feasibility
of using this model for testing the antisense oligonucleotides
synthesised within the Department of Radiation Oncology.
Untreated and PHA treated lymphocytes were kept in
culture for up to 72 hours and c-myc protein levels were
determined by Western blotting. Samples of 2 x 107 lympho-
cytes were removed at various times after PHA stimulation,
lysed, and total protein was assayed using the BCA micro
method prior to electrophoresis and transfer to nitrocellulose
membranes. Using a number of commercially available anti
c-myc antibodies the expected bands of c-myc protein did
not appear at early time points though intense c-myc protein
bands appeared in the 72 hour PHA treated samples. Lysates
of MOLT4, Raji, HMY, UC, Colo 320, and HT29/5 cell
lines all presented clear c-myc protein bands. Colo 320 cell
lysates produced detectable bands of c-myc protein even
when one hundredth of the protein loaded for lymphocytes
was used. These results suggest that either the reported early
rise in c-myc protein levels in stimulated lymphocytes did not
occur under the conditions of our experiments or, it was
orders of magnitude lower than the rise we have observed at
72 hours, and hence undetectable.
This work was sponsored by the Cancer Research
Campaign.
The characterisation of cell lines from mink lung following
oncogene transfection
M.Z. Khan, R.I. Freshney, A.-M. McNicol, D. Spandidos
& D.J. Kerr
CRC Department of Medical Oncology, University of
Glasgow, Royal Infirmary and Beatson Institute, Glasgow,
UK.
The mink lung cell line MVILU (ATCC CCL64) has been
transfected with c-myc, and normal and activated H-ras (see
abstract Kerr et al.) and the isolated cell lines designated
MV1LU (parental), MLMCGM1-1 (c-myc), MLH06N1-4
(H-ras), MLH06T1-4 (activated H-rasl). These lines have
been characterised by morphology, immunocytochemistry,
and in vitro and in vivo growth kinetics. There are minor
morphological differences with the TI-4 line showing grea-
test signs of diminished contact inhibition, and focus forma-
tion. All the lines stain positively with cytokeratin antibody
(AE3, ICN). Growth rate and saturation density is higher in
T1-4 (td:14.2 h; s.d.:1.2 x 106 cells cm 2) and N1-4 (td:14.1 h;
s.d.:1.1 x 106 cells cm-2) than in the parental line (td:19.5 h;
s.d.:5.7 x105 cells cm-2) and MI-i (td:18.2 h; s.d.:5.7 x 105
cells cm-2) This distinction is reflected in their growth as
xenografts where TL.1 has a high take rate (100%) the
shortest latent period (7d) and initial doubling time (4d), the
parental line has a low take rate (20%), longest latent period
(60d) and doubling time (9d). MI-I and Nl-4 have inter-
mediate values with a possibility that NI-4 shows more
aggressive growth than MI-1; both grow much more vigour-
ously than the parental line. Transfection with all the
oncogenes has increased growth in vitro and in vivo.
Although activated H-rasl has the greatest effect, normal H-
ras is still almost as active as H-rasl, and gives tumours
whose histological appearance' suggests greater similarity, in
terms of local invasion, to H-rasl than to either the c-myc
transfected or the parent line.
C-erbB2 oncoprotein expression in malignant and
non-malignant tissues
A. McCann, P.A. Dervan, W.J. Gullick & D.N. Carney
Mater Misericordiae Hospitatl Dublin, Ireland; and
Hammersmith Hospital, London, UK.
Using a polyclonal antiserum (21N) to the C-erbB2 onco-
protein, a total of 405 primary malignant human tumours
and 94 non-malignant tissues were immunohistochemically
assessed for over-expression of this putative transmembrane
receptor protein. Of the 405 primary carcinomas investigated
17% (32/191) of the breast carcinomas, 4% (1/23) of the
colorectal adenocarcinomas, 2% (1/48) bladder carcinomas
and 1% (1/84) of the non-small cell lung neoplasms showed
intense positivity for this oncoprotein predominantly located
at the cell membrane. None of the small cell lung carcinomas
(n =23), prostatic adenocarcinomas (n =23) or malignant
melanoma samples (n=10) were positive for the oncoprotein.
Of the 94 non-malignant conditions investigated none of the
benign breast conditions (n =45), non-malignant bladder
conditions (n= 15), benign prostatic hyperplasia samples
(n= 10), normal colorectal biopsies (n=11) and non-involved
lung resection margins (n = 13) showed any positivity for the
C-erbB2 oncoprotein. This study shows that over-expression
of the C-erbB2 oncoprotein is common in breast cancer but
relatively rare in the other malignancies investigated. In
addition over-expression appears to be confined to the
malignant phenotype.
pSV3neo transfection and gamma radiation sensitivity of
human bladder tumour cells
C.N. Parris, J.R.W. Masters, M.H.L. Green & C.F. Arlett
Institute of Urology, University College London, St Paul's
Hospital, London; and MRC Cell Mutation Unit" Sussex
University, UK.
Normal fibroblasts can be transformed by transfection with
the plasmid pSV3neo (Mayne et al., Exp. Cell Res., 1986,
162, 3630). Following transfection, the cells are less sensitive
to the lethal effects of ionising radiation (Arlett et al., Int J.
Radiat. Biol., in the press). This change in sensitivity may be
due to the introduction of SV40 T-antigen, contained within
pSV3neo. To extend these findings, we transfected pSV3neo
into three bladder cancer cell lines RT112, T24 and HT1376.
T-antigen expression in the transfected cells was confirmed
by immunocytochemical staining. Gamma radiation sensitivi-
ties of the parental lines and transfected sublines were
compared following exposure to a range of doses of gamma
radiation. Do and D values were derived from a least
squares linear regression plot of log cell survival against dose
of irradiation in Gy (see table).







Following transfection with pSV3neo, the gamma radia-
tion sensitivities of the tumour cell lines were unaltered.
These data indicate that in cells already transformed, trans-
fection with SV40 T-antigen does not modify radiation
sensitivity.
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DNA repair fidelity and recombination proficiency in B16
melanoma metastatic variants
B.A. Usmani, G.V. Sherbet & J. Lunec
Cancer Research Unit, Medical School, University of
Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH,
UK.
The progression of malignant tumours appears to be asso-
ciated with a rapid generation of metastatic variants, which
has been attributed to an increased level of genomic instabi-
lity. Although elevated mutation frequencies have been mea-
sured in highly metastatic tumours, the mechanisms involved
are not known. In order to assess the contribution of DNA
repair and recombination defects we have compared the
efficiency of these processes between low (F1) and high
metastasis (BL6 and ML8) variants of the B16 murine
melanoma.
No difference in the rate or extent of DNA strand break
religation was detected using the hydroxylapatite technique.
The fidelity of DNA strand break repair was assessed by
transfection with the plasmid PMH16, which carries two
selectable genes, neo and gpt. Enzymatic breaks were pro-
duced within the gpt coding region. Following transfection,
cells were subjected to sequential selection for intact neo and
gpt genes. High metastasis variants showed a greater fidelity
of religation of the cut gpt gene.
Chromosomal recombination frequencies were measured
by the method of Subramani and Rubnitz (J. Mol. Cell
Biol., 5, 659) using a plasmid (pDR1) which contains an
interrupted neo gene. In preliminary experiments, the fre-
quency of successful recombination of a functional neo gene
following chromosomal integration of the plasmid was found
to be - 1 x 10-I for the Fl (low metastasis) clones and
5 x 10- for the highly metastatic BL6 cells.
Thus, although the more metastatic variants show a
greater fidelity of DNA strand break religation, they appear
to exhibit a reduced capacity for successful homologous
recombination. Defective homologous recombination may
contribute to the elevated mutation frequency reported for
highly metastatic tumours.
Protection of oncogene anti-sense oligodeoxynucleotides
against degradation by serum exonuclease
D.M. Tidd, A.F. Chapman, D.G. Spiller, C.C. Goodwin,
J.A. Tidd & H.M. Warenius
CRC Department of Radiation Oncology, University of
Liverpool, Clatterbridge Hospital, Wirral L63 4JY, UK.
An anti-sense oligodeoxynucleotide 15-mer complementary
to the first 5 codons of the human c-myc gene has been
reported to inhibit myc protein synthesis in and proliferation
of PHA stimulated lymphocytes and HL60 promyelocytic
leukaemia cells in culture (Wickstrom et al., Proc. Natl Acad.
Sci. USA, 1988, 85, 1028). Cultured Colo 320 and HT29/5
human colon carcinoma cells were shown to synthesize high
concentrations of myc proteins and yet their proliferation
was unaffected by the same anti-sense oligodeoxynucleotide
(50,iM). It was subsequently demonstrated that the general
applicability of anti-sense oligodeoxynucleotides in studies of
oncogene function in cultured tumour cells would be limited
by their rapid degradation by nucleases present in the serum
components of the tissue culture media. In order to deter-
mine the relative contributions of endonuclease and exo-
nuclease activities in fetal calf serum to oligodeoxynucleotide
destruction, we have tested chimeric molecules protected
against exonuclease attack with terminal methylphosphonate
diester linkages. These experiments indicated that 3'-
phosphodiesterase is the predominant nuclease responsible
for oligodeoxynucleotide degradation by fetal calf serum and
that substantial increases in the lifetime of intact molecules
in tissue culture medium may be achieved by blocking their
3'-termini against attack by this enzyme.
This work is supported by the Cancer Research
Campaign.
Identification of hypervariable regions containing multiple
tandem repeat sequences by electron microscopy
L.W. Coggins & M. O'Prey
Beatson Institute for Cancer Research, Garscube Estate,
Switchback Road, Bearsden, Glasgow G61 IBD, UK.
Hypervariable regions (HVRs) in eukaryotic genomes consist
of multiple tandem repeats of short (10-50 bp) sequences.
The copy number differs between individuals, providing
useful markers for 'genetic fingerprinting' and creating res-
triction fragment length polymorphisms (RFLPs) some of
which show linkage with diseases including cancers.
A HVR, termed the variable tandem repeat (VTR)
sequence, lies 3' to the human Harvey-ras oncogene. It
consists of 29 copies of a 28 bp sequence in a 6.5 kb DNA
fragment molecularly cloned in plasmid pT24. Supercoiled
pT24 molecules cut with a restriction enzyme, and identical
molecules subsequently denatured and reannealed to form
homoduplex DNA, were examined with an electron micro-
scope. Some molecules in both preparations contained partly
hybridised pairs of small single-stranded DNA loops. The
structures varied in morphology, but all mapped to the
position of the VTR and could be derived by misaligned
hybridisation of these sequences. In preparations of a plas-
mid carrying a major HVR (228 x 17 bp), 3' to the human
alpha-globin gene complex, many homoduplex molecules
contained larger, more morphologically variable and more
complex looped structures. Electron microscopy thus
provides a method of mapping multiple tandem repeat
sequences with respect to restriction enzyme sites in cloned
DNA.
The design of DNA sequence recognition elements based on
berenil
T. Jenkins, C. Laughton & S. Neidle
CRC Biomolecular Structure Unit, Institute of Cancer
Research, Sutton, Surrey SM2 5NG, UK.
The anti-trypanosomal agent berenil has been shown to
possess DNA-sequence recognition ability. Footprinting stu-
dies have revealed preferential binding to clusters containing
at least 4 A-T base pairs (Portugal & Waring, Eur. J.
Biochem., 1987, 167, 281). We are interested in berenil as a
'building block' in the design of larger DNA-sequence
recognition elements. X-ray crystallographic and molecular
modelling studies have shown that berenil adopts a confor-
mation isohelical with B-DNA, enabling efficient binding in
the minor groove (Pearl et al., Nucl. Acid Res., 1987, 15,
3469). Subsequent molecular modelling on more than 36
DNA-octamer/berenil complexes has revealed a preference
for binding with a 3 base-pair stagger and an energetic
preference for A-T over G-C sequences in accord with DNA
footprinting results. These modelling studies have been
extended to investigate the potential of berenil-based oli-
gomers for the recognition of longer stretches of DNA. A
dimer has been designed which will bind, with minimal
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Molecular mechanics calculations indicate that the dimer
maintains the A-T sequence preference of berenil over the
extra base-pairs.
32P-postlabeliing analysis of the effect of butylated
hydroxyanisole on the level of DNA adduction by
aristolochic acid in the rat forestomach and liver
M.N. Routledge & R.C. Garner
Cancer Research Unit, University of York, Heslington, York
YOJ 5DD, UK.
The non-genotoxic food anti-oxidant butylated hydroxy-
anisole (BHA) has been shown to cause cancer in the
forestomach of the rat (Ito et al., JNCI, 1983, 70, 343) but
the mechanism by which this occurs is not clear. In this
study the sensitive 32P-postlabelling assay (Randerath et al.,
PNAS, 1981, 78, 6126) was used to confirm that BHA does
not bind to DNA of the rat forestomach (target organ) or
liver (non-target organ) when administered by oral intu-
bation at a dose of 1 gkg 1 body weight daily for fourteen
days.
The effects of co-dosage of BHA with aristolochic acid
(AA), a potent genotoxic forestomach carcinogen that forms
DNA adducts detectable by postlabelling (Schmeiser et al.,
Carcinogenesis, 1988, 9, 297) on AA adduct formation, were
investigated. Male Wistar rats were dosed orally with either
BHA (1 gkg body weight - day-I in corn oil) and AA (1
mg kg body *eight - day - in water) or corn oil and AA
for 5 days in groups of three. DNA was extracted from liver
and forestomach and 32P-postlabelled using the nuclease P1
enhancement method (Reddy & Randerath, Carcinogenesis,
1986, 7, 1543).
It was observed that levels of aristolochic acid DNA
adduction, as determined by Cerenkov assay, were two or
three times higher when BHA was co-administered, as
compared to when it was not, in both liver and forestomach.
This work confirms that BHA does not bind to DNA
directly or indirectly in vivo. Increased levels of adduction by
aristolochic acid in the presence of BHA could be due to the
induction of microsomal enzymes by BHA, leading to
increased production of activated metabolites of AA.
Immunological detection of AFB1-DNA and BSA adducts
in animal and human tissues
J. Harrison & R.C. Garner
Cancer Research Unit, University of York, Heslington, York
YOJ 5DD, UK.
Aflatoxin B1 (AFB1) is a potent hepatocarcinogen for a
number of laboratory animal species and has been epidemio-
logically linked to human primary hepatocellular carcinoma
(PHC) in areas of the world with high food contamination.
The effect of chronic human exposure to low AFB1 levels
are unknown. New sources of exposure for the Western
world have recently been identified in imported foods, such
as dried figs.
We have developed immunological methods to concentrate
and quantify both AFB1-DNA and protein adducts using a
mouse monoclonal antibody raised against AFB1. Recovery
of AFB,-guanine or AFB,-FAPy, the major in vivo DNA
adduct, is greater than 90% using immunoaffinity chromato-
graphy, followed by ELISA, for quantification. Recovery of
AFB1-lysine, the major serum albumin adduct, was also
greater than 90%.
Using the combination of immunoaffinity concentration
and ELISA, we have identified AFB1 adducts in rats dosed
with AFB1 and humans thought to be exposed to this
mycotoxin. Our work demonstrates the feasibility of human
dose monitoring to environmental carcinogens.
The quantitation of benzo(a)pyrene DNA adducts detected in
mouse skin and lung tissue comparing 32P-postlabelling and
scintillation counting
M.M. King & R.C. Garner
Cancer Research Unit, University of York, Heslington, York
YOJ 5DD, UK.
Cigarette smoking is a major cause of lung cancer;
approximately 50 carcinogenic chemicals are known to be
associated with cigarette smoke. Carcinogen DNA adduct
formation is recognised as a key factor in the initiation of
chemical carcinogenesis. Using highly-sensitive 32P_
postlabelling (Reddy et al., Carcinogenesis, 1984, 5, 231),
smoking-related adducts have been demonstrated in the
human placenta (Everson et al., JNCI, 1988, 80, 567) and a
linear relationship has been established between adduct levels
in the human lung and daily and lifetime-cigarette
consumption (Phillips et al., Nature, 1988, 336, 790).
However, when the same sets of samples were examined
using a highly-sensitive immunoassay, there were inconsist-
encies when results from 32P-postlabelling and immunoassay
were compared.
In order to investigate this problem further, controlled
animal experiments have been set up. Groups of 4 mice were
topically treated with a smoking-related chemical carcinogen,
Benzo(a)pyrene. The dose range of carcinogen applied was
between 0.1Mmol and 0.9ymol BP, each sample containing
150pCi (3H)BP. DNA from skin and lung tissue was
analysed for adduct content, initially by 32P-postlabelling,
using the nuclease P1 enhancement method (Reddy &
Randerath, Carcinogenesis, 1986, 7, 1543) and scintillation
counting. 32P-postlabelling results showed greater adduct
levels in skin DNA than lung DNA and a clear dose-
response relationship was obtained in both tissues. The range
of adducts detected in the lung DNA was between 1.4
adducts per 108 nucleotides at the lowest dose and 1 adduct
per 107 nucleotides at the highest dose, as compared to 1.7
adducts per 106 nucleotides and 4 adducts per 106 nucleo-
tides in skin DNA. Scintillation counts also showed greater
adduct levels in skin DNA than lung DNA and a dose-
response relationship in both tissues. The range of adducts in
lung DNA was between 6.2 adducts per 107 nucleotides and
4 adducts per 106 nucleotides, as compared to 1 adduct per
106 nucleotides and 1.6 adducts per 105 nucleotides in skin
DNA. The discrepancies indicated between these results may
affect accurate quantitation of more complex human
samples. The possible reasons for these differences are under
investigation.
Thymidine kinase gene expression in UV-irradiated human
lymphoblastoid (Raji) cells
V.J. McKelvey, L.A.J. Stefani & P.G. McKenna
Biomedical Sciences Research Centre, University of Ulster,
Coleraine BT52 iSA; and NI Centre for Genetic
Engineering, Medical Biology Centre, Queen's University,
Belfast BT9 7BL, UK.
Deficiency of the salvage pathway enzyme thymidine kinase
(TK) in Friend erythroleukaemia cells results in increased
sensitivity to cell killing and mutagenesis following exposure
to a variety of carcinogenic agents including UV light484 THIRTIETH BACR AND FOURTH ACP MEETINGS
(McKenna et al., Cell Biol. Int. Res., 1981, 5, 555; McKenna
et al., Genet. Res., 1982, 40, 207). Work with other
malignant cell lines indicates that TK deficiency only confers
increased sensitivity in those cell lines which are normally
proficient in DNA excision repair (McKenna et al., Somat.
Cell Mol. Genet., 1985, 11, 239).
In this study messenger RNA (mRNA) TK levels were
compared in untreated asynchronous Raji cells and in UV-
treated asynchronous Raji cells at 21 hours following UV-
irradiation. Three doses of UV light were used, namely 2.5, 5
and 1OJm-2. RNA was extracted from control and treated
cultures and Northern blots were prepared. The TK gene
probe was developed by subcloning the 1.4Kb Bam HI
fragment of the plasmid ptk 9, containing the cDNA clone
of the human TK gene (Lin et al., Proc. Natl Acad. Sci.,
1983, 80, 6528) into the riboprobe Gemini 1 transcription
plasmid to obtain the recombinant TKG 9. In vitro
transcription of Bgl 1 restricted TKG 9 produces a very
efficient TK RNA hybridisation probe.
Autoradiographs were obtained following 24 hours
exposure of TK hybridised Northern blots, and showed
significantly elevated TK mRNA levels in Raji cells
following 2.5 Jm-2 UV-irradiation relative to controls. The
TK mRNA levels were observed to decrease towards control
level with increasing dose of UV light, perhaps as a
consequence of very severe cell damage resulting in cell
death. The importance of TK in DNA repair of damage
induced by low doses of light is indicated.
This Research was supported by the Ulster Cancer
Foundataion.
Transcutaneous oxygen tension - a guide to effective
perfusion in regional chemotherapy for malignant melanoma
D.S. Byrne, R. Blackie, J. Hughes, G. Burnside,
R.M. MacKie & A.J. McKay
Department of Surgery, Gartnavel General Hospital,
Glasgow; Department of Medical Oncology, Glasgow
University; and Department of Dermatology, Western
Infirmary, Glasgow, UK.
Isolated limb perfusion (ILP) is an established mode of
regional cancer therapy. Its principal application is in the
treatment of malignant melanoma of the extremities using
melphalan. The surgical technique is very similar in most
centres; however, the criteria by which an adequate blood
flow is achieved in the isolated limb are complex and
variable.
We have measured transcutaneous oxygen tension (P,cO2),
blood flow and intra-arterial pressure in 20 patients
undergoing ILP.
We observed a positive correlation between P,cO2, blood
flow and intra-arterial pressure. We also found a positive
correlation between P,cO2 and tissue melphalan, levels
measured by HPLC.
We conclude that P,cO2 monitoring offers a simple and
useful measurement of the adequacy of tissue perfusion
during ILP. Using this measurement it should be possible to
ensure maximal tissue delivery of melphalan.
Relationship between reductive drug metabolism of
anthracyclines in microspherical form and anti-tumour
activity
N. Willmott, J. Cummings, E. Marley & J. Smyth
Effect of 06-alkylguanines on eukaryotic DNA methylase
P.A. Hepburn & M.J. Tisdale
CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Aston University, Birmingham B47, UK.
The effect of 06-alkylguanines on eukaryotic DNA
methylase has been investigated using enzyme from mouse
L1210 ascites tumour cells partially purified through an
Ultragel AcA34 column. While N7-methylguanine 3-
methyladenine, 1-methyladenine and 5-methylcytosine had no
effect on the activity of DNA methylase, the methylation of
DNA in vitro was inhibited by 06-methylguanine in a dose-
related fashion. The inhibition could be counteracted by
inereasing the specific activity of the enzyme, and was not
reversible by dialysis, suggesting that the 06-methylguanine
may be reacting with the enzyme protein in a manner
analogous to that with the repair-enzyme, 06-methylguanine
methyltransferase (06MeGMT). Other 06-alkoxyguanines
were less effective in inhibiting the DNA methylase in vitro
in the order ME>Et> Bu. Treatment of GM892 cells, which
lack 06MeGMT, with 0.1 mM 06-methylguanine produced
an initial decrease in DNA methylase activ,ty within 1-2 h
of treatment, followed by an increase in enzyme levels to
approximately twice the starting value. This increase in
enzyme activity was not inhibited by cycloheximide
suggesting an increased processing of pre-formed enzyme.
The inhibition of DNA methylase by 06-methylguanine was
not observed in Raji cells which are proficient in
06MeGMT. These results suggest that DNA methylase may
react with 06-methylguanine in cells lacking 06MeGMT, an
effect which would have important consequences in terms of
carcinogenesis and gene expression.
Department of Pharmacy, University of Strathclyde,
Glasgow; and ICRF, Department of Medical Oncology,
Western General Hospital, Edinburgh, UK.
Protein microspheres were developed as a carrier to (a)
target incorporated cancer therapeutic agents to solid
tumour deposits, (b) increase duration of exposure t6
incorporated agent. To investigate the latter point with
respect to anthracyclines a model was developed involving
direct intratumoral injection of a SC growing rat carcinoma
(SpiO7) with drug in solution or in microspherical form. We
have reported increased activity of doxorubicin in
microspherical form compared to drug in solution. This was
associated with retention of drug in tumour tissue and
reductive metabolism to 7-deoxyaglycones following
administration of 60pg doxorubicin as measured by HPLC
with fluorescence detection (mean peak metabolite
concentration (48h): microspheres 3.7pgg-1; solution
<0.05pgg-1). In contrast to doxorubicin, 4'-
deoxydoxorubicin in microspherical form was no more active
than drug in solution and less active than doxorubicin in
microspherical form. Thus, if the reductive metabolism
observed were an important determinant of activity of
doxorubicin in microspherical form it would be predicted
that 4'-deoxydoxorubicin in this form would not be
metabolised to 7-deoxyaglycones in tumour tissue. The
metabolic profile of 4'-deoxydoxorubicin in tumour tissue
was in fact similar to doxorubicin in that following
intratumoral injection of 60pg of parent drug in
microspherical form reductive metabolism to 7-
deoxyaglycones occurred (mean peak metabolite
concentration (24h): microspheres 2.7pgg-1; solution
0.3pgg-1). Thus, as regards doxorubicin, reductive
metabolism of drug in tumour tissue when injected in
microspherical form does not appear to be an importantTHIRTIETH BACR AND FOURTH ACP MEETINGS 485
component of its increased activity; however, these results
have implications for the type of chemotherapeutic agent
that could benefit from incorporation into microspheres.
The influence of drug exposure parameters on the predictive
value of the clonogenic assay in an experimental tumour
model
R.M. Phillips, M.C. Bibby & J.A. Double
Clinical Oncology Unit, University of Bradford, West
Yorkshire BD7 JDP, UK.
The clonogenic assay has been shown to be a poor predictor
of response in numerous clinical trials. Several problems may
contribute to the poor prediction of tumour sensitivity, one
of which is the inadequate representation in vitro of drug
exposures achieved in vivo. The aim of this study was to
assess whether or not standard methods of 'imitating' in vivo
drug exposures (i.e. 1 hour exposure at achievable drug C x t
parameters - protocol A) provide a better or worse
prediction of tumour response than an assay where drug
exposures in vitro and in vivo are identical (protocol B). In
protocol B, tumour cells, derived from an ascitic murine
adenocarcinoma of the colon, MAC 15A tumour were first
treated with cytotoxic drugs in vitro (at achievable plasma
drug C x t exposures for 1 hour) before being either
inoculated into mice to assess anti-tumour effects in vivo or
cultured in vitro to determine clonogenic cell kill.
Adriamycin (ADR), 5-fluorouracil (5-FU), methotrexate
(MTX), ThioTEPA (TSPA) flavone acetic acid (FAA) and
TCNU were used. In protocol A, all drugs were
administered intraperitoneally at their respective maximum
tolerated doses, and anti-tumour effects were assessed on the
basis of differences in the median survival time of treated
and control groups. The predictive value of both protocols A
and B were good for ADR and TCNU (true positive
predictions) and for MTX and FAA (true negative
predictions). For 5-FU and TSPA, a poor correlatton (false
positive prediction) exists using both protocols A and B
suggesting that other factors apart from achievable drug
exposures have a significant influence on the final outcome
of chemotherapy in vivo. For ADR, TCNU, MTX and
FAA, the use of standard drug C x t principles in the
analysis of the clonogenic assay does correlate well with
tumour response in the MAC 15A tumour model.
Acute dosing with pyridoglutethimide and aminoglutethimide
inhibits hepatic cytochrome P450
Z. Damanhouri, P.J. Nicholls & H.J. Smith
Welsh School of Pharmacy, UWCC, PO Box 13, Cardiff
CFI 3XF, UK.
Pyridoglutethimide (PD), a new aromatase inhibitor (Al)
with greater selectivity of action on steroidogenesis than
aminoglutethimide (AG), is currently on clinical trial in
women with breast cancer. Such patients often receive
several drugs concurrently and it is important to assess the
potential of any new agent for drug interactions, a common
site being hepatic cytochrome P-450. This work compares
the ability of equimolar oral doses of PD (56mgkg-1) and
AG (60mgkg-1), when administered acutely (1 h
beforehand), to inhibit the P-450-dependent metabolism of
various compounds. In female mice, pentobarbitone (P,
45mgkg-1 i.p.) hypnosis, zoxazolamine (Z, 120mgkg-1 i.p.)
paralysis and 14CO2 exhalation t05 after 14C-antipyrine (A,
0.3,uCi i.p.) were significantly (P<0.05) prolonged by PD
and AG (with P from 28+4 to 202+28 (PD) and 172+26
(AG) min; with Z from 52+4 to 94+10 (PD) and 81 +7 (AG)
min; with A from 20+1 to 43+1 (PD) and 31 +2 (AG) min).
Pretreatment of female rats with PD and AG elevated 1 h
plasma levels of phenytoin (l5mgkg-I i.p.) from 2.7+0.5 to
7.3+0.8 (PD) and 4.5+0.3 (AG) Mg ml-1. A similar effect
occurred with the 4h plasma levels of dicoumarol (8mgkg-I
p.o.) from 26+2 to 35+1 (PD) and 35 +2 (AG). The hypo-
glycaemic action of tolbutamide in rats was potentiated by
both PD and AG. The oxidation of 4-nitro-anisole and
dicoumarol by rat liver microsomes was non-competitively
inhibited by PD and AG. The results demonstrate that both
drugs inhibit hepatic P-450. This effect should be recognised
as a potential source of drug interactions when these AIs are
initially given to patients already receiving a variety of
medication.
Kinetic basis for paediatric dosage of vincristine
B.J. McDermott, M. Kohli, R.F. Stevens, A.J.P. Pearson
& P. Moris-Jones
Department of Therapeutics and Pharmacology, The Queen's
University of Belfast; Royal Manchester Children's Hospital;
and The Medical School, University of Newcastle upon
Tyne, UK.
Because of immaturity in hepatic conjugation, the kinetics of
vincristine (VCR) in infants will vary significantly compared
with older children and adults, so that especially young
children may not tolerate standard doses calculated on the
basis of body surface area (BSA). An infant's BSA is
relatively large in proportion to body weight (BW).
Furthermore, about 25% of children with malignancy are
malnourished at presentation and although the BSA does
not change significantly, lean body mass may be altered
considerably. In this study we compared the disposition of
VCR given by the standard schedule of 1.5mgm 2 with that
recommended for children with BSA less than 1 m-2 of
0.O5mgkg-1 (Woods et al., J. Pediatr., 1981, 98, 642). The
investigation was of randomised cross-over design in 6
patients (5M, IF) of median age 38 months (14-75), BW
13.9kg (9.1-26.5kg) and BSA 0.59m2 (0.40-0.90m2). On the
basis of BW, median dose given was 0.75mg (0.46-1.25mg)
whereas it was 0.88mg (0.60-1.35mg) when calculated
according to BSA and the associated increase was 27% (8-
56%). Correspondingly, the median AUC' was greater after
doses based on BSA (2.39 gml-1 min-1) than on BW
(1.86jgml-P min-1). When AUCO values associated with
each schedule were correlated with age, they decreased with
increasing age and the slope of the regression line describing
the relationship with BSA was greater than that with BW,
by a factor of 3, such that in the youngest child, the AUC'
increased by 72%. Dosage calculated according to BSA in
infants, therefore, results in proportionately greater exposure
to the drug, which may account for the increased incidence
of VCR-related neurological toxicity, compared to older
children.
N-(2-hydroxypropyl)methacrylamide copolymer-antibody
conjugates have greatly reduced inmunogenicity
P.A. Flanagan, B. Rihova, V. Subr, K. Ulbrich &
R. Duncan
CRC Laboratory, University of Keele, Staffordshire
ST5 5BG; Institute of Microbiology and Institute of
Macromolecular Chemistry, Czechoslovak Academy of
Sciences, Prague, Czechoslovakia.
N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers
have been developed as drug-carriers (Kopecek & Duncan,486 THIRTIETH BACR AND FOURTH ACP MEETINGS
J. Controlled Rel., 1987, 6, 315). Copolymer conjugates can
be synthesised to incorporate pendant, oligopeptide side-
chains terminating in either bound drug, or a suitable
targeting residue, such as an antibody molecule. Immuno-
genicity is already known to be a major problem associated
with the administration of antibodies to patients.
Two strains of mouse (A/J high responder; BlO, low
responder; Rihova et al., Thymus, 1988, 8, 161) were
immunised with HPMA copolymer (100lpg), IgG or
IgG-HPMA copolymer conjugate (100pg protein). The
first immunisation used complete Freund's adjuvant
subcutaneously, followed by two further immunisations
intraperitoneally using alum precipitate. Mice were
exsanguinated on the seventh day after the final
immunisation and the serum separated by centrifugation
(lOOOg, 10 min, 4°C). The antibody titres (IgG and IgM)
raised against the above antigens were determined using the
ELISA technique. There is up to a 250-fold reduction in the
antibody titer (IgG) raised in mice against human
immunoglobulin fraction G (IgG) after conjugation to
HPMA copolymer. Cross-reactivity of antisera revealed that
polymer is externally disposed in the conjugate and this
(masking' of the protein antigen may account for the
decrease seen. Experiments in rats have showed up to a 220-
fold reduction in antibody titre (IgG) raised against murine
monoclonal antibodies B72.3 and A5B7 after conjugation to
HPMA copolymer. The activity of such conjugates
incorporating drug will shortly be investigated.
Development of a monoclonal antibody-based competitive
ELISA for measuring mitozantrone levels in serum
Confirmation of a prognostic index for metastatic breast
cancer
J.F.R. Robertson, R.I. Nicholson, I.O. Ellis, C.W. Elston
& R.W. Blamey
Nottingham City Hospital; and Tenovus Institute, Cardiff,
UK.
We have previously reported an index of prognosis from the
time of diagnosis of metastatic breast cancer based on 4
factors: grade and oestrogen receptor (ER) of the primary
tumour, site of initital metastases, disease free interval (DFI).
Retrospectively 3 groups were identified with index scores
of <8, 8-16.5 and >16.5. Survival between the 3 groups
was significantly different (X2 = 146.6; 2 d.f., P<0.001).
We have applied the prognostic index prospectively to a
second group of 81 patients who have presented subsequent
to calculating the index. The patient population and survival
at 18 months for both the original group of patients and the
prospective group are shown in the table.
Prognostic index group
Patient group A B C
Original
no. of patients (%) 70 (37) 79 (41) 42 (22)
% survival at 18 months 67 37 0
Prospective
no. of patients (%) 26 (32) 26 (32) 29 (36)
% survival at 18 months 100 33 14
Survival in the prospective group of patients was
significantly different between the prognostic groups
(X2=81.18; 2d.f.; P<O.001). This index allows accurate
prediction of the prognosis in systemic disease and should
therefore be used for allocating patients to different
treatment regimens.
S.U. Flavell & D.J. Flavell
Monoclonal Antibody Unit, University Department of
Pathology, Southampton General Hospital, Southampton
S09 4XY, UK.
A monoclonal antibody (NO-1) was produced against the
small anti-cancer drug Mitozantrone (Mr 517.4) (Lederle
Laboratories, Gosport, Hants, UK) following the
immunization of a BALB/c mouse with Mitozantrone-
Keyhole Limpet Haemocyanin conjugate. Employing this
monoclonal antibody in a competitive ELISA with
Mitozantrone-bovine serum albumin (MZ-BSA) as solid
phase antigen, it was possible to accurately and reproducibly
detect levels of Mitozantrone in pooled human serum in the
range from 0.5 to 40ngml-1. The assay displayed good
reproducibility with intra-assay coefficients of variation of
between 1.4 and 7.02% being obtained for sextuplicate
samples at concentrations of Mitozantrone in serum ranging
from 0.1 to 80ngml-1.
The demonstration that it is possible to raise a specific
monoclonal antibody against a very small molecule and the
subsequent successful development of an ELISA for this
molecule indicates that similar monoclonal-based immuno-
assays may be possible for other small molecules where
quantitation at low levels by standard techniques poses
analytical difficulties. Another possible role for a cytotoxic
drug antibody of this nature may be in drug targetting where
it may be possible to construct a bispecific antibody with
anti-tumour cell specificity in one FAB arm and anti-drug
specificity in the other. Thus, drug could be targetted to the
tumour cell surface by antibody without the need for
covalently coupling the drug to the antibody.
An evaluation of mucin-like carcinoma associated antigen
(MCA) in breast cancer
E.H. Cooper, M.A. Forbes & A.K. Hancock
Unit for Cancer Research, University of Leeds, Leeds
LS2 9NL; and Bradford Royal Infirmary, Bradford
BD9 6RJ, UK.
Serum levels of mucin-like carcinoma associated antigen
(MCA) were measured in 80 healthy women, 109 patients
with breast cancer at presentation and in samples taken from
60 patients with active metastatic breast cancer. MCA levels
in controls were <1.0-19.6Uml-1, median 6.2Uml-1: the
levels in patients with stages 1-111 at presentation were not
significantly different to controls. Longitudinal studies over
5-9 years in 20 patients with stage I and II disease who had
remained tumour free showed a narrow MCA range for each
individual patient, but the mean and range of a single
measurement in a further 63 of these patients were similar to
those of the normal controls. Rising MCA levels occurred in
12/14 patients who developed metastases in 2-8 years after
surgery. 80% of patients with active metastatic disease had
MCA levels > 15 Uml 1. MCA levels fell during clinical
responses to therapy in metastatic cancer. In the context of
follow up serum MCA levels appear to be a sensitive
indicator of metastatic disease; caution is required in the
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Serum thymidine kinase - a tumour marker in advanced
breast cancer
J.F.R. Robertson, K. O'Neill, G. McKenna &
R.W. Blamey
City Hospital, Nottingham; and University of Ulster,
Coleraine, UK.
The enzyme thymidine kinase (TK) is associated with DNA
synthesis. TK serum levels were studied in normal controls,
primary breast cancer (PBC) and advanced breast cancer
(ABC). All values are given as pmolml-lh- .
Group No. ofpatients Mean value s.d.
Normal 20 4.22 + 1.08
PBC 60 6.22 + 1.24
ABC 20 9.79 +7.56
Analysis of variance P<0.005
Twenty PBC patients were followed up after mastectomy
by serial 3 monthly TK levels in the disease free interval.
Four patients have developed systemic recurrence with a
mean serum value of 14.3.
Ten ABC patients had serial TK levels 2 monthly during
the first 6 months of primary hormone therapy. External
assessment of response to treatment by UICC criteria has
been obtained. The serum values fell in all 5 responders
(mean 9.12-4.78) and rose in all 5 progressors (mean
8.62-38.56).
Serum TK reflects stage of disease being significantly
elevated in advanced breast cancer both on serial estimations
and in comparison with controls. Serial TK levels in ABC
patients measures response to systemic therapy. TK appears
to be a useful biochemical marker in breast cancer.
Ki67 in primary breast cancer
J.F.R. Robertson, K. Walker, R.I. Nicholson,
A.P. Locker, I.O. Ellis & R.W. Blamey
Nottingham City Hospital; and Tenovus Institute, Cardiff,
UK.
Ki67 is a proliferation antigen associated with actively
cycling cells. One hundred and four patients with primary
operable breast cancer had Ki67 measured on tumour
sections by immunocytochemistry. Forty-five patients were
positive for Ki67 binding (>5% tumour nuclei stained).
There was an excellent correlation with grade and mitotic
index.
No. of No. of
tumours tumours
positive for positive of
Ki67 (%) Ki67 (%)
Grade I (n=23) 6 (26%) Mitotic index 1 (n=42) 9 (21%)
Grade II (n=33) 12 (38%) Mitotic index 2 (n= 16) 12 (75%)
Grade III (n=48) 33 (69%) Mitotic index 3 (n=46) 30 (65%)
x2=30.7; 2d.f.; P<0.001 x2-21.95; 2d.f.; P<0.001.
There was no correlation between Ki67 and tumour size
nor lymph node stage. Patients with Ki67 tumours had an
increased number of recurrences.
Ki67 measured by immunocytochemistry may provide the
basis of a semi-automated method for histological grading.
Can growth fraction as estimated by Ki67 staining give an
early prediction of the response of tumours to therapy?
L.G. Durrant, S.A. Watson, N.C. Armitage, R. Charnley
& D. Morris
Cancer Research Campaign Laboratories, University of
Nottingham; and Department of Surgery, University
Hospital, Nottingham, UK.
9i67 is a monoclonal antibody which recognises an antigen
in all cycling cells. Freshly disaggregated colorectal tumour
cells were stained by indirect immunofluorescence with Ki67
monoclonal antibody and analysed on the flow cytometer.
The assay accurately estimated growth fractions of 5% and
above.
Fifty colorectal tumours have been analysed and 10% of
them had a growth fraction in excess of 30% and 29% a
growth fraction between 10 and 30%. A further 28% had
growth fractions of between 10 and 5% and the remaining
33% had growth fractions below 5%. The accuracy of the
assays was good as the standard error of duplicate sample
was 7.3 +3.3%. However, if the tumour was subdivided into
small biopsies prior to separate disaggregations a large
variation in growth fraction was observed (57+20%).
This did not correlate with specific areas i.e. central
necrotic area low proliferation and the extreme edges a high
proliferation index. There was also variation between the
growth fraction of biopsies taken at sigmoidoscopy and the
growth fraction of the resected tumour. It was hoped to use
this latter technique to assess treatment administered post
sigmoidoscopy and prior to tumour resection. However, due
to the sampling variation it is unlikely to be informative.
In highly proliferating tumours, with a presumably bad
prognosis, therapy may reduce the growth rate significantly
compared to placebo treated patients and this would be
rapidly detected by this assay.
Measurement of placental alkaline phosphatase in benign and
malignant pleural effusions
R.J. Fergusson, L.W. Duncan, F.G. Hay, TJ Fisken,
M.A. McIntyre, J.E. Roulston & R.C.F. Leonard
Departments of Clinical Oncology and Pathology, Western
General Hospital and Department of Clinical Chemistry,
Royal Infirmary, Edinburgh, UK.
Placental alkaline phosphatase (PLAP) has been shown to be
produced by a variety of human tumours. It has been
extensively studied in ovarian cancer where it may have
some use as a tumour marker. As it has been found in
association with lung cancer we have assessed its potential as
a diagnostic marker of malignancy in pleural fluid. Sixty
patients with 'benign' and malignant pleural effusions were
studied: 12 had a primary lung tumour, 23 had evidence of
secondary tumour (7 ovary, 7 breast, 3 adenocarcinoma, 3
lymphoma and 3 others) and 25 had a non malignant
aetiology for their effusion (10 cardiac failure, 5 related to
infection, 2 rheumatoid, 1 TB, 1 thromboembolism disease
and 6 unknown). Patients in this last group were followed
for up to one year to exclude an occult malignancy. PLAP
was measured using the two monoclonal antibodies H17E2
and H317 by an ELISA method. Mean pleural PLAP levels
(±s.d.) were similar in the groups with primary lung cancer
(0.48 IU1- 1 +0.47) and with 'benign' effusions
(0.54ml-1 +0.86). PLAP levels in patients with secondary
tumours appeared higher (0.88 IU1- +2.02) but this may be
explained by the higher levels associated with ovarian
primaries (2.16 IUP- +3.5). Smoking habits did not488 THIRTIETH BACR AND FOURTH ACP MEETINGS
influence PLAP levels. We conclude that the measurement of
PLAP in pleural fluid is unhelpful as a diagnostic aid apart
from perhaps identifying a small subgroup of patients with
metastatic ovarian tumours.
Serum CA19-9, CA15-3, CA72-4 and TATI in epithelial
ovarian cancer (EOC) role in relation to CA125
J. Fisken, A. Bowman, R.C.F. Leonard, J.E. Roulston
University Department of Clinical Chemistry and Clinical
Oncology, Royal Infirmary, Edinburgh EH3 9YW, UK.
Serial measurement of tumour markers (TMs) is a feasible
means of determining response to chemotherapy and
detecting preclinical recurrence of EOC, without recourse to
second-look laparotomy, where appropriate markers exist.
Serum CA125 now has well established but limited clinical
utility, not all tumours secrete it, thus highly specific '2nd-
line' TMs to CA125 are required. We investigated the above
4 novel TMs in this respect, all reportedly elevated to
varying degrees in EOC, by assaying serial serum samples
from 42 patients with EOC. The number of samples with
elevated levels are shown below.
No. of CA125 CA153 CA199
patients >35Uml-1 >3OUml-1 >33Uml-
Stage
I+11 19 27/82 15/96 18/96
III+IV 23 51/86 40/109 37/109
Histology
Serous 17 41/73 30/93 16/93
Endometrioid 14 26/55 20/63 17/63
Mucinous 8 8/34 4/40 10/40
No. of CA72-4 TATI >I Marker
patients >IOUml-I >20pl-1 elevated
Stage
1+11 19 8/34 9/66 41/96
III+IV 23 10/41 36/61 85/109
Histology
Serous 17 3/30 24/55 64/93
Endometrioid 14 8/27 13/35 43/63
Mucinous 8 6/15 3/31 15/40
With a slight degree of overlap, TATI, CA19-9, CA15-3
and CA72-4 were elevated in 20, 8, 4 and 3 cases respectively
where CA125 was negative, and a further 4, 16, 10 and 1
cases respectively awaiting CA125 assay. A previous study
found TATI to be a more specific marker of endometrioid
EOC than CA125 (Fisken et al., Br. J. Cancer, Abstract in
press). TATI and possibly CA19-9 look promising '2nd-line'
markers of endometrioid and mucinous EOC respectively,
however further clinical details are required to assess the
role, if any, of these markers in relation to CA125.
A prospective assessment of the tumour markers CA50,
CA195 and CEA in prediction of tumour stage and
recurrence in colorectal cancer
P.M. Sagar, E.H. Cooper & P.J. Finan
Department of Surgery and Unit for Cancer Research,
Leeds General Infirmary, Leeds LSJ 3EX, UK.
CA50 and CA195, two newly developed carcinoma-
associated carbohydrate antigens, may be clinically useful
markers in monitoring patients following curative colorectal
cancer surgery. We report a study comparing CA50 and
CA195 with CEA in the prediction of stage and recurrence
in 102 consecutive patients. Pre- and serial postoperative
serum samples were obtained. CA50 was assayed using a
time resolved fluoro-immunometric method and CEA and
CA195 by radioimmunoassay. Patients were reviewed 3
monthly with clinical examination, liver function tests, faecal
occult bloods, 6 monthly liver ultrasound and annual pelvic
CT and colonoscopy. Median follow-up was 16 months
(range 3-25). Preoperative serum levels of all three markers
increased with Dukes' stage and discriminated localised
(Dukes' A, B) from advanced disease (CEA and CA50
P<0.01, CA195 P<0.002, Mann-Whitney U test). The
markers failed to differentiate Dukes' A from B and only
CA50 differentiated Dukes' C from D (P<0.05). Out of 80
patients who underwent a potentially curative resection, 23
have shown a subsequent elevation in one or more tumour
markers, but only 8 have developed proven recurrence-
marker elevation preceding clinical detection in 4 (median
lag period 3 months). Two patients have developed
recurrence without marker elevation. CA50 and CA195
proved no better than CEA in predicting recurrence. The
value of these tumour markers remains to be determined.
Tumour biochemistry and response to treatment studied by
clinical 31p magnetic resonance (MR) spectroscopy
C.J. Twelves, M. Lowry, D. Porter, M. Smith, P. Heasley,
P. Harper, R.D. Rubens & M.A. Richards
Clinical Oncology Unit and Division of Radiological
Sciences, Guy's Hospital, London SEJ 9RT, UK.
Animal tumours have characteristic biochemical features
which change in response to chemotherapy (CT) or
radiotherapy (RT) before alterations in tumour size are
detectable. Human metabolism can now be studied non-
invasively with MR spectroscopy. We have obtained 20 MR
spectra from 7 patients (pts) with large superficial tumours
(4 breast cancer, 3 lymphoma). Serial spectra were obtained
in 4 pts after CT or RT.
Examinations were made on a 1.5 Tesla Philips Gyroscan
imaging and spectroscopy system with a purpose built 5 cm
diameter surface coil placed over the tumour. Tumour size
was measured and coil position confirmed with MR images.
31P spectra were acquired and processed using a standard
technique. Peak heights of phosphomonoesters (PME),
inorganic phosphate (Pi), phosphodiesters (PDE), phospho-
creatine (PCr), y-, a- and ,B-ATP were measured and ratios
for PDE/PME and fl-ATP/Pi calculated.
Breast cancers studied before treatment were characterised
by high PME, PDE and Pi and by" low P-ATP/Pi.
Lymphoma spectra differed in that more PCr was detected.
Spectra in 1 breast cancer treated with RT and 1 lymphoma
treated with CT showed marked changes within 24 hrs of
starting treatment, before tumour size changed. Both pts
subsequently responded clinically. In contrast, spectra from 2
other pts (1 breast cancer, 1 lymphoma) did not appear to
change with treatment, and neither patient responded
clinically.
Tumour metabolism can be studied by MR spectroscopy
and changes in tumour biochemistry after treatment
detected. These biochemical changes reflect alterations in
membrane turnover (PME+PDE/PME) and cellular energy
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The pedometer: an objective assessment of qualitj of life?
J.H. Davies, P.R. Malone, S.J. Harland & R.J. Shearer
Department of Urology, St Georges Hospital and St Peters
Group of Hospitals and Institute of Urology, London, UK.
Subjective assessment of quality of life of cancer patients is
an important part of clinical trials and is usually based on a
scoring system. Those in use (Karnofsky and Eastern Co-
operative group scale; ECOG) are, however, time consuming
and open to criticism of interpretation. Objective assessment
of patients response includes the measurement of
haematological, biochemical and radiological indices. We
have evaluated the use of an electronic pedometer as an
objective measurement of patients mobility before and
during treatment for advanced urological cancers. Eight
patients with advanced prostatic cancer were treated with an
aromatase inhibitor. One patient with disseminated testicular
cancer was treated with combination chemotherapy. Daily
totals were recorded on a Scotcade 'Pe-Do' pedometer before
and during treatment. Subjective assessment was by the
ECOG scale. Standard objective parameters were measured
regularly. In the patient with testicular cancer, a marked
reduction in steps following chemotherapy occurred which
recovered before the next course. Five of the patients with
prostate cancer rapidly progressed, marked by a reduction in
steps recorded. Three patients responded subjectively to
therapy but pedometer readings showed a decline in steps
which matched the progression in objective parameters. In
this small group of patients, the pedometer score provided a
simple useful objective measurement of their response to
therapy.
Effect of insulin and ketone bodies on tumour growth and
host body weight in a cachexia model
S.A. Beck & M.J. Tisdale
CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Aston University, Birmingham B4 7ET,
UK.
We have utilised the MAC16 adenocarcinoma of the mouse
colon as an experimental model of human cachexia where
weight loss occurs without a reduction in food or water
intake. Weight loss produced by the MAC16 tumour is
characterised by a loss of body fat and muscle dry weight,
which increases in direct proportion to the tumour burden,
and is associated with the presence of circulatory catabolic
factors, which degrade host muscle and adipose tissue in
vitro. Both insulin and 3-hydroxybutyrate inhibit the lipolytic,
and proteolytic activity in vitro, and thus a comparison has
been made between the effects of daily insulin injections and
a ketogenic diet on weight loss and tumour growth in the
MAC16 model. Weight loss was significantly reduced by
both a ketogenic diet (80% of calories supplied as medium
chain triglyceride) and by administration of 20 U insulin
kg- 1 day-1 without an alteration in either water
consumption or total calorie intake. At the end of the
experiment the tumour weight in animals fed a ketogenic
diet was significantly lower than those consuming the normal
laboratory diet, while in animals treated with insulin the
tumour weight was 50% greater than controls. The
enhancement of tumour weight by insulin was prevented by
the concurrent administration of sodium 3-hydroxybutyrate.
Both carcass fat and muscle dry weight were elevated in
animals fed the ketogenic diet or administered insulin when
compared with controls. These results suggest that both
insulin and ketone bodies are effective in prevention of
weight loss in cancer cachexia, but that insulin
administration may be associated with an enhanced tumour
growth rate.
A new method of screening for preclinical cervical cancer by
analysing the glycoprotein content of cervical scrapes
G.A. Turner, L. Arvanitakis, J.M. Monaghan &
S. Thompson
Department of Clinical Biochemistry, The Medical School,
Newcastle upon Tyne, NE2 4HH; and Gynaecological
Oncology Unit, Queen Elizabeth Hospital, Gateshead NE9
6SX, UK.
Cervical cancer is a significant cause of female mortality. It
has a clearly defined preclinical phase which can be detected
by cytological examination of a cervical smear. Although a
full call and recall system has now been introduced in an
attempt to reduce the mortality rate, insufficient experienced
cytologists are available to cope with the workload. If a
biochemical method could be developed that could rapidly
screen out all the negative specinmens this could result in a
90% saving in manpower costs. The test described here may
offer this possibility. This involves removing a cervical
specimen using an endocervical brush and placing the cells
and mucus into a close-fitting tube containing NP40 and
Tris buffer. Glycoproteins are extracted from this solution
using Sepharose-coupled wheat germ agglutinin and their
composition analysed by SDS/PAGE and silver staining
(Thompson et al., Clin. Chim. Acta, 1987, 167, 217). Extracts
from 10 women who had normal smear cytology showed
very consistent electrophoretic patterns. In contrast 10
women who exhibited various degrees of dyskaryosis showed
different and more complex patterns; the most consistent
changes were increases in components with M, of 40-45 kDa
and 55-57kDa and a reduction in components at 75-80kDa.
One of the components in the 55-57kDa region has been
tentatively identified as cytokeratin. These results suggest
that negative and positive cervical cytology can be easily
distinguished. As yet no qualitative or quantitative
relationship has been found between the electrophoretic
patterns and the degree of cytological abnormality.
Increased calmodulin inhibition and cytotoxicity against the
MCF-7 breast cancer cell line by iodinated derivatives of
tamoxifen
R. McCague, M.G. Rowlands, I.B. Parr, M. Jarman &
P.M. Goddard
Section of Drug Development, Institute of Cancer Research,
Sutton SM2 SNG, UK.
Since the discovery by Lam that tamoxifen is a competitive
antagonist of the activation of cyclic-AMP phospho-
diesterase by calmodulin, inhibition of calmodulin action has
been suggested to contribute to the inhibition by tamoxifen
(TAM) of hormone responsive breast cancer growth.
Possibly, optimisation of calmodulin antagonism in agents
that also bind to the oestrogen receptor (ER) might provide
a strategy for the development of improved drugs for breast
cancer treatment.
We have recently discovered that 4-iodotamoxifen (IT)
(E-1-(4-(2-(dimethylamino)ethoxy)phenyl)-1-(4-iodophenyl)-2-
phenyl-l-butene) has greater affinity for cytosolic ER than
tamoxifen. Unlike 4-hydroxytamoxifen (OHT) where the
increased ER binding contrasts with a decreased calmodulin
inhibition, we now find that IT is a more potent calmodulin490 THIRTIETH BACR AND FOURTH ACP MEETINGS
inhibitor than TAM and the iodinated analogue (IPT) with
dimethylamino replaced by pyrrolidino is more potent still.
IC50 values for the inhibition of cyclic-AMP phospho-
diesterase activity increase in the order IPT= 1.4pM,
IT=2.3 uM, TAM=6.75 M, OHT= 19gM. This order
correlates with that of the cytotoxicity against MCF-7 cells
in monolayer culture after exposure to drug for 24h, a
timespan insufficient to observe the antagonism of hormone
mediated proliferation. Thus at 10gM of drug, numbers of
viable cells, as percentage of control were IPT=29, IT=29,
TAM = 104, OHT = 129. The iodinated tamoxifen analogues
did not show this increased cytotoxicity against the
oestrogen independent Walker rat carcinosarcoma and
L1210 murine leukaemia cells in culture where all the four
antioestrogens gave IC50 values between 22 and 34pM.
The above results support the viewpoint that calmodulin
could play a role in the inhibition by tamoxifen of oestrogen
'responsive tumour growth, and indicate a possible
superiority of iodinated tamoxifen analogues in the
treatment of hormone dependent breast cancers.
Steroid hormones and receptors in human breast carcinoma
V. Ramalingam & P. Govindarajulu
(PGR). PGR levels can be turther induced (approximately
10-fold), by exposing cells to oestradiol, (10-9 M), for 5 days.
Both tamoxifen and medroxyprogesterone acetate (MPA) are
growth inhibitory. Short-term (1 week) culture of cells in
medium lacking phenol red and containing dextran
charcoal stripped serum resulted in a pronounced slowing of
growth rate and PGR was undetectable. ER levels were
unchanged and PGR could be induced by oestradiol
treatment. Growth rate could be slowed further by
tamoxifen treatment whilst MPA now stimulated growth as
did oestradiol. Long-term (3 months) culture of cells in
oestrogen-free conditions resulted in a return to a growth
rate similar to that of cells grown under routine culture
conditions. ER could no longer be detected using a whole
cell exchange binding assay, while PGR expression had risen
to a level normally associated with oestrogen induction.
PGR could not be further induced by oestradiol treatment.
Long-term oestrogen withdrawn cells retained tamoxifen
sensitivity and were again sensitive to growth inhibition by
MPA, but physiological concentrations of oestradiol were
without effect. This phenotype has remained stable for two
years.
Our data would be consistent with the proposal that ZR-
75-1 cells adapt to growth in the absence of oestrogen by
expressing ER which has lost the ability to bind oestradiol
and is biologically active in the absence of the hormone.
Department of Endocrinology, P.G. Institute of Basic
Medical Sciences, Madras 600 113 and Department of
Zoology, Tagore Arts College, Pondicherry 605 008, India.
To evaluate the hormone dependency of human breast
cancer, the measurement of oestrogen (ER) and progesterone
(PR) receptors were undertaken. Circulating oestradiol and
progesterone were also measured to correlate with the
receptor status. Ninety-eight premenopausal and 80 post-
menopausal subjects with carcinoma breast and 30 normal
subjects were included. Premenopausal subjects were further
classified into follicular, midcycle and luteal phases.
Receptor determinations were performed by Scatchard
analysis of dextran coated charcoal method in both the
cytosol and nuclear fractions. Serum oestradiol was
significantly elevated in 28% of premenopausal and 34% of
post-menopausal subjects with carcinoma. However, serum
progesterone was decreased only in the luteal phases of
premenopausal subjects and unaltered in post-menopausal
subjects. The percentage of ER positive subjects was 79 and
36 and that of PR positive subjects was 64 and 29 in the
cytosol and nuclear fraction, respectively. Both pre-
menopausal and post-menopausal subjects showed no
difference in their receptor concentration while significant
variations were observed among follicular, midcycle and
luteal phases. No clear correlations were observed between
serum hormones and their receptor status. Efforts are in
progress with many more subjects to make a correlation
among serum hormones, tissue hormones and their receptor
status.
High progesterone receptor levels in human breast cancer
cells (ZR-75-1) adapted to growth under oestrogen free
conditions
H.W. van den Berg, M. Lynch & J.H.J. Martin
Department of Therapeutics and Pharmacology, The Queen's
University of Belfast, Belfast BT9 7BL, UK.
Under routine culture conditions in medium containing fetal
calf serum associated oestrogens and the weakly oestrogenic
pH indicator phenol red, ZR-75-1 human breast cancer cells
express oestrogen receptor (ER) and progesterone receptor
Epidermal growth factor receptor expression in primary
breast tumour tissue
J. Lunec, S. Nicholson, J. Fennelly, C. Parker, G.V.
Sherbet & A.L. Harris
Cancer Research Unit, Medical School, University of
Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK.
Levels of epidermal growth factor receptor (EGFR)
determined by ligand binding assays on primary breast
tumour samples were previously shown to be inversely
correlated with the presence of oestrogen receptors and to be
an indicator of poor clinical prognosis. We have gone on to
investigate the mechanisms which may determine EGFR
levels in breast tumours.
Twenty-seven DNA samples and 19 RNA samples were
probed with EGFR cDNA encoding the external, trans-
membrane and part of the internal region of the receptor.
The results were correlated with EGFR levels determined by
ligand binding for the same tumours. Amplification of the
EGFR gene was detected in 3 out of 11 cases for which
EGFR levels were >70fmolmg-1 membrane protein. For all
16 samples showing <70fmolmg-1, no amplification was
detected. Adjustment for non-random selection of samples
indicated an overall incidence of -3% for amplification of
the EGFR gene. The degree of amplification was 5, 10 and
50-fold.
Analysis of RNA samples for EGFR mRNA revealed a
complex relationship between gene copy number, transcript
levels and the number of receptors. In some cases, high
receptor levels were measured in the absence of either
amplification or high levels of transcription, indicating trans-
lational or post-translational mechanisms for establishing
high levels of receptor. The highest transcript levels were
observed for two of the samples in which gene amplification
was detected and these were associated with high levels of
receptor. For the subset of cases for which EGFR
<100fmmg-1, a significant correlation was found between
receptor levels and EGFR mRNA, demonstrating some
degree of transcriptional determination of receptor levels.THIRTIETH BACR AND FOURTH ACP MEETINGS 491
Receptors for the neuropeptide growth factors bombesin,
bradykinin and vasopressin recognise two classes of
antagonist
P.J. Woll & E. Rozengurt
Imperial Cancer Research Fund, PO Box 123, Lincoln's Inn
Fields, London WC2A 3PX, UK.
Neuropeptides are increasingly recognised as growth factors,
so their antagonists could be useful anti-proliferative agents.
We have shown that bombesin/gastrin-releasing. peptide
(GRP), bradykinin and vasopressin are mitogens in Swiss
3T3 cells and each stimulates a rapid intracellular Ca2+ flux.
Their receptors are distinct as shown by (i) specific cell
surface binding of 1251-GRP and 3H-vasopressin which is
not inhibited by the other mitogens and (ii) the existence
of ligand-specific antagonists (Leu13-W(CH NH) Leu14)
bombesin, (DArg0,Hyp3,Thi5'8,DPhe7)bradykinin and (Pmpl,
OMeTyr2,Arg28)vasopressin which are inactive against
the othermitogens. Incontrast, (DArg1, DPhe5DTrp7'9,Leu1 1)
substance P reversibly inhibits ligand binding, Ca2+
mobilisation and mitogenesis induced by GRP, bradykinin
and vasopressin, but no other growth factors. We suggest
that the receptors for these neuropeptides exhibit two
binding domains. One is ligand-specific and is blocked by the
ligand-specific antagonists. The second domain is common to
the three receptors and is blocked by (DArg1,DPhe5,
DTrp7'9,Leu1l )substance P. Small cell lung cancer (SCLC)
secretes many peptides and hormones including GRP and
vasopressin. (DArg1, DPhe5, DTrp7'9, Leul')substance P
inhibits the growth of SCLC cell lines. We are testing the
receptor model in SCLC cell lines, utilising measurements of
intracellular Ca2+ fluxes.
The biological and the clinical significance of epidermal
growth factor and transforming growth factor alpha in
normal and malignant ovaries
O.J. Owens & R.E. Leake
Department of Biochemistry, Glasgow University, G12 8QQ,
UK.
Epidermal growth factor (EGF) and transforming growth
factor alpha (TGFax) were assayed in 65 samples by a
radioimmunoassay method (The sensitivity of both assays is
between 20pg and 5ng growth factor per 250l of tissue
extract. The cross-reactivity is such that 10pg of EGF will
measure as 40 pg in a TGFa assay and vice versa).
Seventeen samples were from normal ovaries, 6 were from
benign ovarian tumours, 27 were from primary ovarian
tumours, 3 from metastatic deposits in the omentum, 6 had
primary tumours elsewhere and 6 were from second look
operations (ovary 2, nodes 3 and omentum 1). TGF was
found to be present in all normal ovaries and in the majority
of ovarian tumours (85%), while EGF was present in 22%
of normal ovaries and 38% of ovarian tumours. The amount
of TGFa measured ranged from 195 to 1750pgg-1 of wet
tissue in normal ovaries (mean 758pgg-1) while EGF
ranged from 237 to 640pgg-1 (mean 375pgg-.1). In primary
ovarian tumours the value of TGFax ranged from 53 to
4372pgg-1 (mean 964pgg-1), and EGF ranged from 229 to
348pgg-1 (mean 203pgg-1). In summary we can conclude
that TGFa is more frequently found than EGF in both
benign and malignant ovaries and when present exists in
greater quantities. The prognostic significance of these assays
is yet to be established.
Extractable transforming growth factor alpha and epidermal
growth factor in cervical and endometrial cancer
L. Carr & R.E. Leake
Department of Biochemistry, Glasgow University, Glasgow
G12 8QQ, UK.
Transforming growth factor alpha (TGFa) and epidermal
growth factor (EGF) were extracted from malignant
endometrial and cervical tissue by organic solvent extraction.
The growth factors were measured using sensitive radio-
immunoassays (range 20pg to 5ng growth factor in 250p1
tissue extract). The primary antibodies were highly specific,
such that 10pg EGF measured only 40pg in the TGFo assay
and vice versa. In cervix the median value for TGFa was
694pgg 1 tissue (range 206-14,702pgg-1 tissue). Of 13
cervix samples analysed only 3 were negative for TGFa
whereas the majority (10) were negative for EGF (3 positive;
range 82-599pgg- tissue). Endometrial cancer showed a
similar pattern with 6 out of the 15 samples assayed as
positive for EGF (median 759pgg-1 tissue; range 172-
1204pgg-1 tissue). Only one sample was negative for TGFa
(median 1259pgg-1 tissue; range 377-15,517pgg-1 tissue).
Both growth factors are thought to act via the EGF-
receptor. Tumours of the cervix have been shown bio-
chemically and immunohistochemically to express the EGF-
receptor whereas, the majority of endometrial tumours were
shown to be EGF-receptor negative. Thus the site of action
of the endometrial TGFa is, as yet, unclear. As the levels of
the growth factor detected are very variable it will be
interesting to determine the prognostic value of growth
factor levels in both endometrial and cervical cancer.
Regulation of epidermal growth factor receptor synthesis by
ovine and human prolactin
F. Rinaldi & R.E. Leake
Department of Biochemistry, University of Glasgow, G12
8QQ, UK.
A combination of ovine prolactin (1 pgml 1) and epidermal
growth factor (EGF) (0.005ygml-1) was shown to induce
marked growth stimulation (250% increase over control after
four days) in the human breast cancer cell line ZR-75-l. As
the level of EGF receptor (EGF-R) is relatively low in these
cells under control conditions (70fmolmg DNA- I ml-1),
studies were carried out to determine the ability of ovine and
human prolactin to induce EGF-R synthesis. Ovine prolactin
(1 pgml-1) and human prolactin (40ngml-1) were both
shown to induce the synthesis of EGF-R over the same time
course. Peak levels of EGF-R (320 fmol mg DNA-1 ml-1)
were seen at four days after initial exposure to the hormone.
This stimulation was completely abolished by non-toxic
levels of cycloheximide (40nm). Medium conditioned by
prolactin activated cells was also shown to stimulate EGF-R
synthesis in fresh ZR-75-1 cells. These results indicate that
human prolactin induces EGF-R synthesis in human breast
cancer cells through a paracrine mechanism. These
observations may explain the suggestions in the literature
that prolactin can promote breast tumour growth.
Effects of human platelet-poor plasma (PPP) on the growth
of breast cancer cells
T. Simpson & H. Braunsberg
Department of Chemical Pathology, St Mary's Hospital
Medical School, London W2 IPG, UK.
Human breast cancer progression may be determined by the
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(INH) hormones and growth factors, derived from blood or
produced locally, and of receptors for these substances in
and on the cells. The relative importance of autocrine,
paracrine and endocrine effects remains to be established
and we have focused on the latter.
Humah breast cancer cells (MCF-7) were exposed to
media containing charcoal-stripped cell free blood
preparations at concentrations ranging from 1 to 20% v/v.
Since platelets can release INH and STIM factors during
clotting, and freezing of samples reduced STIM but not INH
activity, we studied fresh PPP. With samples from 2 normal
women, a patient with benign breast disease and 3 of 6
breast cancer patients, growth was maximal at 6% (v/v) PPP
and declined at higher concentrations. Two PPPs from
breast cancer patients produced maximal growth at 2% and
two contained an additional STIM factor of low affinity
and/or concentration.
Differences in patterns of blood-borne STIM and INH
factors may, at least in part, account for variations in
tumour growth rates. *Their nature, concentrations and
interactions with each other and with steroid hormones and
other growth factors require full investigation.
A novel endothelial cell growth factor from a human lung
tumour cell line
C. Walker, R. Akhter & D. Pumford
Clatterbridge Cancer Research Trust, J.K. Douglas Cancer
Research Laboratories, Clatterbridge Hospital, Bebington,
Merseyside L63 4JY, UK.
Human lung cancer cell lines have been shown to produce a
variety of growth factors some of which are known to be
angiogenic in vivo (Soderdahl et al., Int. J. Cancer, 1988, 41,
636). The IPT cell line, from a poorly differentiated
bronchial carcinoma, grows at a confluent density for several
months in serum-free DMEM. Medium from this cell line
has been shown to be angiogenic in vivo (Kumar et al., Int.
J. Cancer, 1983, 32, 461) and to stimulate migration,
chemotaxis (Daniel et al., Cell Biol. Int. Rep., 1987, 11, 235)
and proliferation of sparse cultures (Walker et al., J. Cell
Sci., 1987, 87, 739) of human umbilical vein endothelial
(HUV) cells. It supports their clonal growth and long term
serial cultivation and also stimulates the growth of
microvascular endothelial cells and fibroblastic cell types but
not certain epithelial tumour cell lines. Characterisation of
the endothelial mitogen has shown that it is a heat-labile,
acid-stable, proteinaceous material, which does not bind to
heparin-sepharose (Walker et al., 1987). A variety of
techniques has failed to liberate an active fraction of
MW<30 kD suggesting that the factor is not bound to a
high molecular weight carrier molecule or present in
aggregated form. It does not bind to immobilised lentil or
wheat germ lectins, but does have affinity for glycine max
lectin and is eluted from this by N-acetylgalactosamine,
indicating that it is a glycosylated protein. Although we have
not yet purified this factor, our results so far suggest that it
differs from other previously described tumour-derived
endothelial mitogens.
Cell type-dependent modulation of ether lipid-induced
changes in calcium homeostasis by a phorbol ester
C.M. Lazenby, M.G. Thompson & J.A. Hickman
CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Aston University, Birmingham B4 7ET,
UK.
The ether lipids represent a new class of membrane-active
antitumour agents. One of these, SRI 62-834, was reported
by us to bring about a concentration-dependent increase in
the intracellular Ca2+ concentration of HL-60 human
myelomonocytic leukaemia cells which was inhibited by pre-
treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA)
(Thompson & Hickman, Biochem. Soc. Trans., 1988, 16,
278). This led us to suggest that its effect on the membrane
were not those of a detergent-like activity. Treatment of
7.5 x 106 ml-1 K562 human erythroblastic leukaemia cells
with 60,pM SRI 62-834 (below the IC,O) for 10min resulted
in-'a smooth rise in intracellular Ca2+ from 74+4.5nmol to
167.5+ 17.6nmol (n=3), as monitored by the fluorescent
calcium indicator Quin-2. Pretreatment of these cells with
100nmol TPA for 10mins reduced the Ca2+ rise by 78%.
Treatment of 7.5 x 106ml1 V79 hamster fibroblast cells,
grown in suspension culture, with 35,uM SRI 62-834 brought
about a sharp rise in intracellular calcium which
accompanied a loss of membrane integrity: the effects of
35gM SRI 62-834 on this cell line were not inhibited by TPA
pretreatment. We suggest that SRI 62-834 may modulate
membrane function in distinctive ways depending on the cell
type.
Aromatase inhibition by 4-hydroxyandrostenedione in
advanced prostatic cancer
J.H. Davies, M. Dowsett, R.C. Coombes & R.J. Shearer
Departments of Urology and Medical Oncology, St Georges
Hospital; and Biochemical Endocrinology, Royal Marsden
Hospital, London, UK.
Studies have shown the benefit of aminoglutethimide in
patients with advanced prostatic cancer. However, its
mechanism of action is not clear. Although it inhibits a
range of other steroidogenic enzymes, its most potent action
is on the aromatase enzyme which is the final enzyme in the
biosynthesis of oestrogens and this may be its mode of
action. 4-hydroxyandrostenedione (4-OHA) is a more
selective steroidal aromatase inhibitor. We have conducted a
clinical trial of this drug in an attempt to define the role of
aromatase inhibition and of oestrogens in prostate
carcinoma. In a phase I study, 16 patients, who had relapsed
following orchidectomy for advanced prostatic carcinoma,
were given 500mg 4-OHA intra-muscularly weekly.
Complete subjective responses (CSR) were seen in 3 (L8%)
and partial subjective responses (PSR) in 8 (50%) patients.
Average duration of response was 10 weeks. Objectively, 4
(25%) patients had a fall of >50% in serum acid
phosphatase. Androgen levels did not change but oestradiol
levels fell significantly in 5 of 8 patients in which it was
measured. A transient increase in bone pain occurred in 5
(31%) patients. A phase II study is in progress with 20
patients entered to date, receiving the same dose of 4-OHA.
CSR has been observed in 7 (35%) and PSR in 5 (25%)
patients. Prostatic acid phosphatase and prostate specific
antigen fell by >50% in 3 patients who responded.
Aromatase inhibition offers a new approach to the
management of advanced prostatic carcinoma.
Measurement of nuclear pleomorphism and DNA content in
metastatic variants of the B16 murine melanoma using image
analysis techniques
G.V. Sherbet & M.S. Lakshmi
Cancer Research Unit, The Medical School, University of
Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK.
Tumours are notable for the variability in the expression of
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morphology. Nuclear pleomorphism is one of the criteria
used in the histological grading of tumours, but quantitative
objective measurement of pleomorphism has not been
attempted. In the present work, we have used image
processing techniques to measure nuclear pleomorphism
(NPM), integrated nuclear density (IND) and nucleocyto-
plasmic ratio (NCR) in the cell line B16-F1, which is poorly
metastatic to the lung, and B16-BL6, which metastasises
extensively to the lung. A third cell line, ML8, isolated from
metastatic tumour from lungs of an animal bearing a
subcutaneous BL6 tumour, was also studied. This was more
malignant than its corresponding primary line, the BL6.
The Joyce Loebl Magiscan MD was used to measure
NPM, IND and NC in cytospin preparations of cells and
sections of tumours produced by s.c. injection of cells into
syngeneic C57BL/6 mice, both stained with haematoxylin
and eosin. The BL6 cells showed greater pleomorphism than
their metastatic counterparts ML8. NPM of Fl cells was
intermediate between BL6 and ML8. No appreciable
differences were noticed in tumour tissues. The NCR and
IND patterns of the three variant cell lines were similar, but
the profile of IND, which represents DNA content, was
markedly different in the tumours. Fl and BL6 tumours had
one major peak (IND=175) but ML8 had an additional
peak (at IND=425). These data suggest that measurement
of integrated nuclear densities may be more appropriate than
nuclear pleomorphism as a feature of malignancy.
Supported by the North of England Cancer Research
Campaign.
The development of a model of metastatic bladder cancer
using the immune-suppressed mouse
K.M. Joy, C.A. Parry & J. Chowaniec
Department of Histopathology, University College and
Middlesex School of Medicine, London WIP 7LD, UK.
Our immune-suppressed (i/s) mice permit the growth of s.c.
inoculated human bladder cancer cell lines; the resultant
tumours are clinicopathologically similar to the primaries
from which the cells were derived (Joy et al., J. Pathol.,
1981, 134, 335). Some of the tumours (e.g. produced by EJ
cells) metastasise in the mice, but they do not do so
reproducibly.
Several cell lines derived from chemically induced pre-
neoplastic or neoplastic rat bladders are likewise tumorigenic
in our i/s mice, producing transitional or squamous cell
carcinomas which often metastasise, but with variable
frequency and onset time. However, an agar-cloned subline,
RU-CL2, produces transitional cell carcinomas that rapidly
invade the subcutaneous host tissues, including nerve sheaths
and skeletal muscle, and reproducibly metastasise haemato-
genously to the lungs and to the distal lymph nodes. As
early as 35d post-inoculation, metastases resembling the
primary tumours are histologically detectable in the lungs of
some i/s mice; by 50d, multiple metastases are present in the
lungs of all animals inoculated.
RU-CL2 is not tumorigenic in immunocompetent mice.
Substantial tumours form when RU-CL2 cells are injected
into weanling syngeneic rats, but these elicit a vigorous host
response and hence soon regress.
Various animal models of tumour metastasis currently
exist; some, however, involve tail-vein injection of cells, thus
by-passing early events in the metastatic cascade, and
relatively few concern metastasis of epithelial cell types. The
use of RU-CL2 cells in i/s mice offers a model with which to
study factors controlling invasion and metastasis of epithelial
tumours. Because of the relatively short onset time for
'spontaneous' tumour metastasis, this model may also prove
useful for assessment of cancer chemotherapy modalities.
Influence of stromal cells on the phenotype of alveolar
carcinoma cells in vitro
V. Speirs & R.I. Freshney
CRC Department of Medical Oncology, University of
Glasgow, Glasgow, UK.
Production of pulmonary surfactant (PS) is necessary for
normal lung function and its presence is indicative of normal
differentiated lung epithelium. The human alveolar
carcinoma A549 has been found to synthesise and secrete PS
in culture. The aim of this study was to determine the
relationship between stromal cells and A549 in the induction
of PS production by glucocorticoids following previous
observations by Smith (Biochim. Biophys. Acta, 1984, 793,
297; J. Biol. Chem., 1986, 261, 2179). Cells were grown in
filter wells in the presence of either fibroblast conditioned
medium (FCM) or fetal lung fibroblasts (MOG-LF113)
either in direct contact or in high density coculture +0.25gM
dexamethasone (DX). PS was measured by incorporation of
3H choline into disatured phosphatidyl choline. DX was
found to cause a 5-fold increase in PS secretion in cells
cultured alone on filter wells. Cells cultured on a
conventional plastic substrate showed only a 1.5-fold
increase, while those cultured in direct contact showed even
higher levels of PS, a 7-fold increase in the absence of DX
and a 2.5-fold increase in the presence of DX. Cocultures
with A549 growing on the filters and fibroblasts on the
bottom of the dish showed similar increases, implying that
cell contact is not important for PS production. This was
confirmed using FCM where there was a doubling in PS
after 48h incubation. We have partially purified a peptide
from FCM of m.wt. 10-30kDa and pI8.7. It appears to be
heat and alkali stable but unstable to treatment with acid,
trypsin or pronase. Incubation of A549 cells with this factor
can stimulate PS production by some 3-fold. Future studies
will attempt to characterise this factor further and determine
its effects on the growth of A549 xenografts in nude mice.
The NX002 cel line - a new model system to study
differentiation in lung squamous carcinoma
S.P. Langdon, G.J. Rabiasz, L.E. Anderson, A.A. Ritchie
& J.F. Smyth
ICRF Medical Oncology Unit, Western General Hospital,
Edinburgh, UK.
We have derived a new model system to study lung
squamous differentiation. Induced differentiation has been
proposed as a strategy to treat malignant disease (Sartorelli,
Br. J. Cancer, 1985, 52, 293) and since chemotherapy, at
present, is relatively ineffective for the treatment of lung
squamous carcinoma, induced differentiation might represent
a possible approach.
The NX002 cell line was derived from a poorly
differentiated squamous xenograft in its 20th passage which
in turn originated from the primary tumor of a patient with
lung squamous carcinoma. Its morphology has remained
constant over 30 passages.
Terminal differentiation (TD) in normal keratinocytes is
characterised by the attainment of the capacity to form
cornified cell envelopes and also by the production of
involucrin, a protein incorporated into the cornified envelope
at TD. Both these markers are present in the NX002 cell
line. Cornified envelopes are observed after cells have been
incubated in 1.2 M NaCl for 4 hours and then treated with
2.5% SDS. Involucrin was identified immunohistochemically
by the indirect immunoperoxidase method. At early
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form cornified envelopes and 15% are positive for
involucrin. In the NX002 xenograft, areas of squamous
differentiation (cells undergoing keratinisation) were positive
for involucrin.
This model provides an in vitro-in vivo system to study
regulation and modulation of lung squamous differentiation.
Small cell lung cancer cluster 1 antigens are diverse and
inducible in non-SCLC cell lines after sodium butyrate
treatment
F.G. Hay, L.W. Duncan, S.P. Langdon & R.C.F. Leonard
Imperial Cancer Research Fund Medical Oncology Unit,
Western General Hospital, Edinburgh, UK.
The Cluster 1 and Cluster 1-associated antigens were
reported (Souhami et al., Lancet, 1987, 325) to be a locus or
loci of interest characteristic of the small cell [SCLC) subtype
of lung cancer. A group of MoAbs defines these clusters by
reacting strongly with SCLC tumour cells yet showing weak
or negative reactions with other lung cancer cells and most
other epithelial tumours. We have previously reported
however the presence of this group of antigens in well
differentiated ovarian tumour cell lines (Langdon et al., Lung
Cancer, 1988, 4, 62). In further studies the expression of two
Cluster I antigens (123C3 and 123A8) could be induced in
three lung adenocarcinoma cell lines (H23, H125 and A549)
using sodium butyrate, an agent capable of inducing
differentiation in many systems (Langdon et al., Br. J.
Cancer, 1988, 58, 247). Expression of these markers by non-
SCLC cells may indicate that some members of the Cluster 1
and IA group of antigens are not just confined to SCLC,
but may be general markers of differentiation in epithelial
tumour cells. We have examined the effects of sodium
butyrate on the expression of all Cluster 1 and IA antigens
in 3 lung adenocarcinoma cell lines, 6 ovarian tumour cell
lines, 3 colorectal tumour cell lines and 4 SCLC lines. In the
untreated group the MoAbs had activity only with the
SCLC lines and well differentiated ovarian lines whereas,
after 4 days exposure to sodium butyrate, Cluster 1 and IA
antigens were detected heterogenously in all of the above cell
lines. After treatment the SCLC lines showed enhancement
of Cluster IA antigens whereas the other currently identified
Cluster 1 antigens did not change. The data suggest that the
Cluster 1 antigens are diverse in expression and in function.
Development from murine embryo neural crest of cell lines
sharing some characteristics with small cell lung cancer
(SCLC)
M. Clay, C.M. Steel, F.G. Hay, A. Lessells &
R.C.F. Leonard
MRC Human Genetics Unit, Imperial Cancer Research Fund
Medical Oncology Unit; and Pathology Department,
Western General Hospital, Edinburgh, UK.
With the aim of developing transfection recipients for human
SCLC DNA, we identified a novel alternative to the classic
NIH3T3 cell lines by establishing cell lines from explanted
mouse embryo neural crest. The neural crest tissue from
eight-day mouse embryos was micro-dissected and cultured
in an FIO based media. A polycolonal subline grew out and
survived thirty passages over eleven months; and it presents
a range of distinct morphologies which persist despite being
cultured in conditioned medium which normally prevents
differentiation. Five monoclonal colonies, each contact-
inhibited, were eventually cloned and injected into immune-
deprived mice. All five have produced tumour growth
although one has a very slow growth rate. Two of the five
have been maintained in Iscove's serum free medium
suggesting that they may be producing autocrine growth
factors. Characterisation of the cell lines has confirmed their
non-fibroblastic nature; electron microscopy studies have
shown cell junctions, cell processes with possible neurotubule
formation and some neuro-secretory granules compatible
with a neural origin. Cell surface markers for epithelial
antigens and neural antigens are both positive and the cells
contain low molecular weight cytokeratins and neuro-
filaments. These tumorigenic cell lines will be probed for the
presence of N-myc, c-myc and L-myc which we have found
characteristically expressed in SCLC cell lines. Efforts to
enhance the tumorigenicity in mice will be made using
segments of human SCLC DNA for transfection.
Characteristics and interrelationship of two cell lines derived
from a bronchial carcinoma
S. Wright-Perkins, M. Daniel & C. Walker
Clatterbridge Cancer Research Trust, J.K. Douglas Cancer
Research Laboratories, Clatterbridge Hospital, Bebington,
Merseyside L63 4JY, UK.
It has been suggested that carcinomata of both small cell
(SCLC) and non-small cell (NSCLC) types arise from a
common stem cell. Changes in phenotype of lung cancer in
vivo and in vitro have been reported. The IPT cell line,
derived from a poorly differentiated bronchial carcinoma,
consists of large polygonal cells which grow both in
monolayer and in suspension; unlike other NSCLC lines,
confluent monolayers continue to proliferate in serum-free
DMEM unsupplemented with the factors essential for SCLC
cells. A variant line derived from this grows in monolayer as
compact plaques or rods of smaller phase-dense cells which
unlike the IPT cells can be grown in serum-free DMEM
from clonal density; in suspension, these cells form three-
dimensional structures. DNA histograms obtained by flow
cytometry show that the IPT line is hyperdiploid, while the
variant is tetraploid. Immunocytochemical techniques have
been used to test for the presence of various.epithelial and
lung-associated antigens. Continued cultivation of the
variant line results in a cyclical production and loss of IPT-
like cells. Clonal lines of 1PT have been established in order
to investigate whether these can conversely give rise to
variant-type cells. The characteristics of these two lines
suggest their potential usefulness for the investigation of the
interrelationship of various malignant pulmonary epithelial
cells.
Retinoic acid inhibits the transformed phenotype in vitro of
metastatic and non-metastatic bladder cancer cell lines
A. Jones, K. Joy & J. Chowaniec
Department of Histopathology, School of Pathology,
University College and Middlesex School of Medicine,
London WIP 7LD, UK.
The ability of all-trans-retinoic acid (RA) to inhibit the
clonogenicity in soft agar of metastatic and non-metastatic
rat and human bladder cancer cell lines was investigated.
Retinoic acid reproducibly inhibited anchorage-independent
(Al) growth of the well differentiated, papillary, human
bladder cancer cell line RT112 which is non-metastatic in
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bladder carcinoma cell line RU-CL2 which consistently
metastasises in such animals.
For both cell lines, RA-induced inhibition of Al growth
was dose-dependent, the ID50 being approx. 10-9M, though
doses as low as 10-11M RA wvere effective. The increased
inhibition at doses above 10-8M RA was not directly
proportional to dose and, at these levels, the effect of RA
toxicity could not be excluded. However, even at 10-7 M
RA, the inhibition of clonogenicity in agar was dependent.
upon the continuous presence of retinoid, since removal of
exposure of cells to RA resulted in a loss of RA-induced
inhibition. Similarly, dose-dependent RA-induced morpho-
logical changes in monolayer cultures of RU-CL2 were
reversible. By contrast, the morphology of RTI 12 cell mono-
layers was unaffected by the presence of RA.
The inhibition of Al growth of both cell lines was
RA-specific, since the synthetic retinoid, 4-
hydroxyphenylretinamide (4HPR) was ineffective.
Whereas Al growth both of metastatic and non-metastatic
cell lines was inhibited by RA, the morphology of only the
metastatic line RU-CL2 was sensitive to RA. This suggests
that RA modulation of Al growth is independent of the
effrects of RA on cell morphology, consistent with the
proposal that two nuclear RA receptor genes transactivate
the transcription of different target genes (Brand et al.,
Nature, 1988, 332, 850).
Humoral hypercalcaemia of malignancy factor and renal
carcinoma
C.J. Gallagher, J. Mosley, R.T.D. Oliver, J. Martin &
M. Horton
Departments of Medical Oncology, Histology, The London
Hospital; and Department of Exp. Haematology, St
Bartholomew's Hospital, London, UK.
Renal carcinoma is associated with the humoral hypercal-
caemia of malignancy (HHM) syndrome in up to 30% of
patients who have a worse prognosis than those remaining
normocalcaemic.
Parathyroid hormone-related protein (PTHrP) has recently
been identified as one of the factors capable of causing
HHM. We have investigated the presence of PTHrP in
normal and malignant renal tissues by imunoperoxidase
staining of paraffin embedded sections using a rabbit
antiserum to synthetic peptides unique to PTHrP. Ten renal
carcinomas have been examined of which 7 were associated
with hypercalcaemia and 3 were normocalcaemic. Two fetal
kidneys of 23 and 40 weeks gestation were also examined.
Positive staining for PTHrP was found in all renal
carcinoma sections irrespective of the presence or absence of
hypercalcaemia. PTHrP was also found in the adjacent
normal kidney and in sections of fetal kidney. PTHrP was
present in the epithelial cells of the normal renal tubules and
collecting ducts. In the fetal kidney a similar pattern was
seen with staining of both proximal and distal tubules even
at 23 weeks gestation. Some cells in each of the carcinomas
stained although there was considerable variation between
tumours and between cells within any tumour. The presence
of PTHrP in renal carcinomas is consistent with their histo-
genesis from renal tubular epithelium as has been previously
shown by cell surface antigens. Further investigation is
needed to define how tumour derived PTHrP becomes
hypercalcaemogenic.
Novel methods for increasing the number of clones
expressing sensitivity to a cytotoxic agent in a tumour cell
population
K. Maynard & B.T. Hill
Laboratory of Cellular Chemotherapy, Imperial Cancer
Research Fund, Lincoln's Inn Fields, London WC2A 3PX,
UK.
Studies of the mechanisms associated with cellular sensitivity
to antitumour drugs may be useful in devising methods of
circumventing or overcoming drug resistance. Instead of
attempting to assay the drug sensitivity of thousands of
clones in a cell population in order to identify a small
number of sensitive clones, we have used two new methods
to increase the proportion of sensitive clones in a human
tumour cell population. The first procedure, a modification
of a method originally described by Sato and Shiomi (Somat.
Cell Genet. 1979, 5, 193), used cisplatin-treated adenovirus as
a lethal probe to obtain cisplatin-sensitive clones from an
ovrian carcinoma cell line (SK-OV-3). These clones showed a
range of two to seven-fold increased sensitivities to cisplatin
and at least some were deficient at reactivation of cisplatin-
treated adenovirus. The second procedure involved the
development of a new method using temperature-sensitive
adenovirus to increase the number of doxorubicin-sensitive
clones in a cell population. These clones showed a three to
six-fold increase in doxorubicin sensitivity. Some clones
showed cross-sensitivity to other antitumour agents such as
etoposide. Characterisation of these doxorubicin-sensitive
clones may lead to the identification of enzymes involved in
maintaining the normal level of cellular resistance to
doxorubicin. This method using temperature-sensitive
adenovirus may prove generally useful in isolating clones
more sensitive to DNA synthesis inhibitors such as
hydroxyurea and methotrexate.
The use of genetic marking to assess the interaction of
sensitive and multidrug-resistant cells in mixed culture
C. Bradley & J.D. Pitts
CRC Department of Medical Oncology, University of
Glasgow; and Beatson Institute for Cancer Research,
Glasgow, UK.
There is evidence for the transfer of drug resistance from
resistant to sensitive cells in culture. Nitrosourea resistance is
transferred between cells in spheroids (Tofilon et al., Science,
1984, 226, 864). Ouabain resistance is transferred in
monolayer cultures by the rapid diffusion of K+ and Na+
ions through gapjunctions (Corsaro & Migeon, Nature, 1977,
268, 737). The membrane pumps in the ouabain resistant
cells maintain physiological ion concentrations in the
cytoplasms of both cell types. It seems possible, therefore,
that other forms of drug resistance which are dependent on
the cytoplasmic concentration of small ions or molecules
shopld be transferred between cells joined by gap junctions.
We have studied the behaviour of normal (CHO-K1) and
multidrug-resistant (Adrr) Chinese hamster cell lines which
have been shown to communicate through gap junctions.
The CHO-K1 cells have been genetically marked by
transfection with a bacterial f,-galactosidase gene. This
enzyme produces a blue product with appropriate substrate
and allows identification of the marked cells. Monolayers of
cells (CHO-K1 alone, Adrr alone and a 50:50 mixture) were
exposed in multiwell dishes to adriamycin or mitozantrone
for 24 hours, then plated out at 500 cells per dish and a
colony-forming assay performed. The number of blue and
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separately to assess the individual response of the two cell
types. In the individual assays Adrr is 100 x more resistant
to adriamycin and 20 x more resistant to mitozantrone than
CHO-K1. However, in mixed culture the chemosensitivity of
the two cell lines remains unchanged with no evidence of
transfer of anthracycline resistance in this system.
MCF-7 cells express differential drug responses and
mechanisms of resistance following either fractionated
X-irradiation or drug exposure in vitro
ACL=5.8, iodo-ADM= 18.9 and Ro 31-1215= 12.4,
whereas the results for COR-L23 were ADM = 15,
ACL= 1.2, iodo-ADM= 1.8, and Ro 31-1215=4.0. Both
H69/LX4 and COR-L23/R were defective in ADM
accumulation with respect to their parent lines. For H69/
LX4 the ADM content was 30% of the parent and the
corresponding result for COR-L23/R was approx. 65%. We
are currently assessing the accumulation of the anthracycline
analogues in the COR-L23 cell lines, and the effects of
verapamil on chemosensitivity and drug accumulation. It
appears that the presence of P-170 is not necessary for the
drug cross-resistance profile and defective drug accumulation
associated with MDR.
R.D.H. Whelan, L.K. Hosking & B.T. Hill
Cellular Chemotherapy Laboratory, Imperial Cancer
Research Fund, London WC2A 3PX, UK.
Drug resistant sublines of the MCF-7 human breast
carcinoma cell line have been used to establish whether
different mechanisms are expressed or predominate
depending on how drug resistance was induced or selected.
We have therefore developed a series of vincristine-resistant
MCF-7 sublines following fractionated X-irradiation or
intermittent drug exposure in vitro. Drug-selected sublines
expressed a 5-10-fold resistance to vincristine which could be
partly reversed with verapamil and exhibited a pattern of
cross-resistance to other antitumour agents consistent with
the classical multidrug resistance phenotype. This pattern of
reduced drug responses was associated with impaired drug
accumulation and over-expression of a 170kDa plasma
membrane glycoprotein (P-glycoprotein), resulting from
some gene amplification. In contrast, MCF-7 cells which
exhibited a 4-fold resistance to vincristine following exposure
to fractionated X-irradiation, did not express cross-resistance
to adriamycin and had no detectable alteration in drug
transport or over expression of P-glycoprotein. Verapamil
did not potentiate the cytotoxicity of VCR in this subline. In
addition, X-ray pretreated cells showed no modification in
glutathione content or glutathione related enzyme activities,
whereas glutathione S-transferase and peroxidase were signi-
ficantly elevated in drug-selected resistant MCF-7 cell lines.
These data indicate that different mechanisms of resistance
may operate or predominate depending on how resistance
was derived.
Anthracycline cross-resistance and drug accumulation in a
multidrug resistant human lung cancer cell line which does
not express P-170 glycoprotein
H.M. Coley, P.R. Twentyman, P. Workman & J.G. Reeve
MRC Clinical Oncology and Radiotherapeutics Unit, Hills
Road, Cambridge CB2 2QH, UK.
The adriamycin (ADM)-resistant variants of the human lung
cancer cell lines NCI-H69 and COR-L23 show the multidrug
resistant (MDR) phenotype, being cross-resistant to
colchicine, vincristine and VP16. The MDR variant of small
cell line H69 (H69/LX4) shows amplification and hyper-
expression of MDR-1 gene encoding P-170 whereas the
MDR variant (COR-L23/R) of large cell line COR-L23 does
not. We have previously identified a number of
anthracyclines which retain high activity in MDR cells
(including H69/LX4), and have now determined the activity
of these agents in COR-L23/R. The agents studied were
aclacinomycin A (ACL), 4'-deoxy-4'-iodo ADM (iodo-
ADM) and Ro 31-1215. These analogues have specific
modifications at the 9 position of the A ring and/or the
sugar residue. Relative degrees of resistance (i.e. ID50
resistant line/ID50 parent line) for H69 were ADM= 150,
Antisense oligonucleotides complementary to the mdrl gene
(P-glycoprotemi)
C. Clugston & R. Brown
CRC Department of Medical Oncology, Beatson Institute,
Glasgow, UK.
Elevated expression of the mdrl gene, encoding the P-
glycoprotein, increases the resistance of cells to several
naturally occurring chemotherapeutic agents, including
adriamycin. High expression of the mdrl gene has also been
implicated in resistance of tumours to chemotherapy. In
order specifically to inhibit expression of the mdrl gene we
have synthesised complementary oligonucleotides (ONDs) to
the mdrl RNA. The choice of ONDs was based on
computer modelling of secondary structure of the mdrl RNA
and searches for other possible cross-hybridising RNA
species. Adriamycin resistant MCF-7 cells, which have
elevated mdrl expression, are being used as the recipient cell
line. ONDs have been synthesised with phosphodiester
linkage or phosphorothioate linkage and their stability and
efficiency of uptake are being compared. Heat inactivation
of the serum increases the stability of the ONDs by more
than 10-fold. DEAE dextran, polybrene and chloroquine did
not increase stability or were too cytotoxic to the cells.
Sensitivity of the cells to adriamycin is being measured using
a short-term assay, the MTT assay. At present no significant
increase in sensitivity of the cells has been detected but there
are still considerable problems to be overcome with the
intracellular stability of the ONDs and in ensuring sufficient
uptake to inhibit mdrl expression.
Response of chemically and virally induced mouse skin
tumours to doxorubicin
N. Keith, P.J. Mee & R. Brown
CRC Department of Medical Oncology, Beatson Institute,
Glasgow, UK.
Tumours can be induced in mice by treatment with
chemical initiators (dimethyl benzanthracine; DMBA) and
promoters (12-O-tetradecanoyl-phorbol-13-acetate; TPA).
More than 90% of these DMBA/TPA induced tumours have
the same specific A-T mutation at codon 61 in the cellular
Ha-ras gene (Quintanilla et al., Nature, 1986, 322, 78).
Tu-mours are also induced if the DMBA initiation is replaced
by topical application of Harvey murine sarcoma virus
directly to the skin (Brown et al., Cell, 1986, 46, 447). We
have examined the response of these chemically and virally
induced papillomas to the widely used chemotherapeutic
agent, doxorubicin. We observe a greater regression
frequency of virally induced, than chemically induced,
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weeks after a single intravenous injection of 10mgkg-1
doxorubicin 95% of the virally induced papillomas have
regressed but only 20% of those chemically induced. A
larger regression frequency of chemically induced papillomas
(73%) is observed after repeated injections of doxorubicin
(5mgkg-' once per week for 4 weeks). Both chemically
induced and virally induced papillomas show a small number
of tumours which do not regress, even after repeated
doxorubicin injections. At present we are analysing these
doxorubicin resistant tumours for mutations of H-ras genes
and for expression of drug resistance genes: P-glycoprotein
(mdrl) and the acidic form of glutathione S-transferase
(gst-pi).
tross-resistance associated with elevated cellular glutathione
levels occurs with melphalan and photons but not melphalan
and neutrons
R.A. Britten, H.M. Warenius, R. White, J.A. Green &
Browning
CRC Department of Radiation Oncology and Department of
Clinical Biochemistry, Clatterbridge Hospital, Wirral, UK.
Cross-resistance to X-rays associated with elevated
glutathione (GSH) levels following pretreatment with
alkylating agents has been demonstrated in animal and
human cell lines. Also we have shown a 10-fold (P>0.001)
elevation of GSH prospectively in a series of 30 ovarian
carcinoma treated patients by alkylating agents and cisplatin.
Raised glutathione levels may thus be clinically important as
a possible cause for the failure of combined sequential
chemotherapy/radiotherapy regimes. Fast neutrons with less
dependence on peroxyl radical formation for their effects
might also be less affected by elevated GSH than are
photons. We thus tested the effects of photons and neutrons
on our melphalan-sensitive and -resistant OAW42 ovarian
carcinoma cell lines. The melphalan-resistant subline
OAW42/MER was 2-fold more resistant to melphalan than
the parental OAW42 cells. Depletion of GSH by BSO
potentiated melphalan cytotoxicity by 2-5-fold. The chemo-
resistant OAW42/MER cells were 1.75-fold more resistant to
photon irradiation than OAW42 cells, BSO potentiated the
lethality of photon irradiation by 17% in OAW42/MER
cells, but did not have any effect in the parental OAW42
line. OAW42/MER cells were not cross-resistant to neutrons.
We conclude that cross-resistance to photon irradiation
exists in OAW42 cells resistant to alkylating agents. Neutron
therapy is equally effective in both resistant and sensitive
cells, and should possibly be considered as the appropriate
radiation modality in neoadjuvant chemotherapy/
radiotherapy protocols.
Changes in glutathione metabolism following exposure to
alkylating agents in human ovarian tumour biopsies
R.A. Britten & J.A. Green
CRC Department of Radiation Oncology, Clatterbridge
Hospital, Wirral L63 4JY, UK.
The glutathione (GSH)/glutathione-S-transferase (GST)
dependent detoxification process has been shown to have an
important role in alkylating agent resistance. Modulation of
melphalan cytotoxicity has been achieved in animal, and
human tumour cell lines (Green et al., Cancer Res., 1984, 11,
211). Following confirmatory work on the importance of this
mechanism in the human ovarian tumour OAW42 line in
this laboratory, ajid the demonstration of a strong
correlation between GSSG and GST levels (r=0.9), GSH
and GST activity have been studied prospectively in fresh
human ovarian tumour biopsies to determine their clinical
relevance. This study has accrued 50 biopsies from 39
patients, with sequential data available on 5 patients. GSH
levels in patients who had received prior chemotherapy
showed a 10-fold elevation (P<0.001), over those previously
untreated. The increase in GSH levels was directly
proportional to the prior cumulative dose of alkylating agent
received in the sequential biopsies. Within 10 weeks of the
cessation of drug exposure GSH levels had fallen to a basal
level, above that found in untreated patients, which persisted
for up to 25 months. Changes in total GST activity
following chemotherapy did not demonstrate a consistent
pattern, and GST sub-unit analysis is currently being
conducted on these samples. This finding suggests that a
major component of the adaptive cellular response to
alkylating agents may be partially reversible induction of
GSH levels, concurrent with tumour cell subpopulation
selection.
Does aphidicolin glycinate reverse cisplatin resistance?
J. Coffey & J.R.W. Masters
University College London, Urological Oncology Unit, St
Pauls Hospital, 24 Endell St, London WC2H 9AE, UK.
Aphidicolin specifically reversed cisplatin resistance in vitro
in a human ovarian cancer cell line (Ozols et al., AACR,
1988, 29, 526), and has entered phase I clinical trial. To
confirm this observation we compared the cytotoxicities of
aphidicolin glycinate (AG) and cisplatin (CP) alone and in
combination against a cisplatin-resistant human bladder
cancer cell line (RT112-CP) and its sensitive parent (RT112).
Both cell lines were maintained under identical culture
conditions and drug sensitivities were measured after a 6 day
exposure using the MTT assay. The resistant cell line
required approximately three times as much AG or CP to
reduce cell numbers by 50%. A range of concentrations of
CP were combined with three concentrations of AG: one
non-toxic, one marginally toxic (reducing cell numbers by
< 10%) and one causing a 20-30% reduction. The non-toxic
concentration of AG did not modify CP toxicity. However,
the two higher concentrations reduced survival by slightly
more than would be expected if the toxicities were additive
and independent. For example, 500ngml- CP reduced the
survival of RT112-CP to 49%/o, 40ngml-P AP to 68% and
the combination to 25% (expected 33%). In contrast to
Ozols et al. (1988), AP increased the toxicity of cisplatin to
both parent and resistant lines to the same small degree.
Thus, these data do not 'provide evidence that AG
specifically reverses CP resistance, but do indicate that AG
produces a small potentiation of CP toxicity.
Studies on cross-resistance patterns and chromosome changes
in cisplatin-resistant human bladder and testicular cell lines
M.C. Walker, J.M. Parrington, L.F. West &
J.R.W. Masters
Urological Oncology Unit, St Paul's Hospital, 24 Endell St,
London WC2; and MRC Human Biochemical Genetics Unit,
UCL, Stephenson Way, London NW1, UK.
Cisplatin is the most active single agent in the treatment of
advanced testicular germ cell tumours and transitional cell
carcinomas of the bladder. However, development of
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Cisplatin-resistant cell lines, designated SuSa-CP and RT112-
CP, were derived in vitro from a human testicular tumour
cell line (SuSa) and a bladder carcinoma cell line (RT112) by
continuous exposure to cisplatin. Patterns of cross-resistance
to other agents commonly used in treatment of bladder and
testis tumours were investigated. The responses of cells to a
range of concentrations of cisplatin, carboplatin, VP-16,
methotrexate (MTX), Adriamycin (doxorubicin) and bleo-
mycin were compared using a tetrazolium dye (MTT) assay.
Approximate levels of cross-resistance are shown in the
table; figures are IC50 of resistant line/IC50 of parental line.
Drugs
Cis- Carbo- Adria- Bleo-
Cell line platin platin MTX VP-16 mycin mycin
RT112-CP 10.0 9.9 6.6 1.9 1.0 2.8
SuSa-CP 2.1 2.0 3.0 1.8 1.0 1.2
Modal chromosome numbers were obtained from orcein-
stained metaphase spreads. These were: RT112 47; RTI12-
CP 43; SuSa 52; SuSa-CP 53. G-banding revealed major
differences between parent and resistant cell lines, including
chromosome losses, gains and translocations. However, the
pattern of alterations was not consistent between the cell
lines.
06-Alkylguanine-DNA alkyltransferase expression and
glutathione transferase action in MAC tumours correlate
with intrinsic resistance to nitrosoureas and chlorambucil
in vitro
J.M. Lunn, J. Carmichael, M.C. Bibby, J.A. Double &
A.L. Harris
Cancer Research Unit, University of Newcastle upon Tyne,
Medical School, Framlington Place, Newcastle upon Tyne
NE2 4HH; and Clinical Oncology Unit, University of
Bradford, Bradford, West Yorkshire BD7 JDP, UK.
The dimethylhydrazine-induced mouse colon adeno-
carcinomas (MAC tumours) display ranges of responsiveness
to commonly used cytotoxic drugs. In order to assess the
relevance of two proposed resistance mechanisms, we have
measured the levels of 06-alkylguanine-DNA alkyl-
transferase (O6AT) and glutathione transferase (GSHT) in
MAC13, MAC15, MAC16, MAC26 and MAC30T tumours.
O6AT was determined by incubating a 3H-Me labelled DNA
substrate with tumour extracts. GSHT activity was assessed
using chlorodinitrobenzene as substrate. Levels of O6AT
ranged from <20fmolmg-1 protein (MAC13) to
80fmolmg-1 protein (MAC26), increasing levels of O6AT
correlating with increasing resistance to MeCCNU.
Decreased resistance of MAC26 to TCNU probably reflects
improved drug delivery of the more water soluble
nitrosourea in this well vascularised tumour. Levels of
GSHT were highest in MAC16 tumours, being five times as
great as those in MAC15, MAC26 and MAC30T tumours.
The relative activities correlated well with the range of
resistance shown to chlorambucil. Thus, resistance to
nitrosoureas could be related to the removal of 06_
alkylguanine lesions from the DNA, while resistance to
chlorambucil was more related to detoxification by
glutathione transferase.
Identification of a relationship between glutathione
metabolism and sensitivity to doxorubicin or cisplatin in a
range of human tumour cell lines
L.K. Hosking, R.D.H. Whelan & B.T. Hill
Cellular Chemotherapy Laboratory, Imperial Cancer
Research Fund, London WC2A 3PX, UK.
Differences in total glutathione content (GSH), may explain
altered drug responses of human tumour cell lines (Bedford
et al., Chemico-Biological Interactions, 1987, 61, 1).
Therefore total GSH content and associated enzyme
activities have been determined in a series of twenty parental
and drug-resistant human tumour cell lines derived following
fractionated X-irradiation or drug exposure in vitro. These
cell lines exhibited differential sensitivities to both
doxorubicin and cisplatin as judged by colony formation
following 24 h drug exposures. Drug concentrations reducing
cell survival by fifty percent ranged from 2-60 and 30-450
ng per ml for doxorubicin and cisplatin respectively, while
total glutathione levels were between 10-80nmol per mg of
cellular protein. The relationships between GSH content or
certain related enzyme activities and drug sensitivities were
statistically analysed using linear regression. Correlation
coeficient values of >0.75 indicated that GSH content may
be a determinant of cellular sensitivity to both cisplatin and
to doxorubicin. Glutathione reductase (GR) and glutathione
peroxidase (GP) activities may influence cellular sensitivity to
cisplatin, as suggested by correlation coefficients >0.6, but
no correlations were identified for glutathione S-transferase.
Statistical analysis of the data obtained using parental cell
lines only demonstrated a similar pattern of correlations.
Glutathione metabolism in human tumour cell lines may
therefore influence cellular sensitivity to certain antitumour
agents.
06-Alkylguanine-DNA-alkyltransferase levels in human testis
and bladder tumour cell lines
M.C. Walker, J.R.W. Masters & G.P. Margison
Urological Oncology Unit, St Paul's Hospital, 24 Endell St,
London WC2H 9AE; and CRC Department of
Carcinogenesis, Paterson Institute for Cancer Research,
Manchester M20 9BX, UK.
The cytotoxic effects of chloroethylnitrosoureas (CNU) are
mediated by the formation of interstrand crosslinks that
originate from an initial chloroethylation of the 06-position
of guanine in DNA. The enzyme 06-alkylguanine-DNA-
alkyltransferase (ATase) can repair this monoadduct and
hence prevent crosslink formation. Thus cellular sensitivity
to CNU appears to be determined by the level of ATase in
the cell.
Testicular tumour cells are sensitive to many anticancer
agents, including cisplatin (CP) (Walker et al., JNCI, 1987,
79, 213). Preliminary to studying the cytotoxicity of CNU,
we measured ATase levels in 5 testis and 5 bladder tumour
cell lines, and CP-resistant sublines SuSa-CP (testis) and
RT112-CP (bladder). ATase was measured in each cell line
by incubation of cell extracts with 3H-methylnitrosourea-
methylated DNA: calculations were based on protein-
limiting values and expressed as fmol mg-' total protein.THIRTIETH BACR AND FOURTH ACP MEETINGS 499
Cell line testis HL GH 1618K
ATase (fmolmg-1) 121 81 230
Cell line, bladder T24 HTJ197 HTJ376
ATase (fmolmg-1) 718 20 520
Cell line testis GCT27 SuSa SuSa-CP
ATase (fmolmg-1) 4 259 450
Cell line, bladder RT4 RTJ12 RTJ12-CP
ATase (fmol mg 1) 278 396 450
Both testis and bladder cell lines showed a wide range of
ATase levels. Interestingly, both of the CP resistant cell lines
had higher ATase levels than their corresponding parernt line.
Further studies are in progress to measure the sensitivity of
the cell lines which display widest differences in ATase levels
to a CNU and to the monofunctional agent methyl-
nitrosourea.
Cross-resistance studies with quinazoline inhibitors of
thymidylate synthase (TS) against two methotrexate
(MTX)-resistant sublines of the L1210
J.A.M. Bishop, A.L. Jackman, L.R. Hughes &
A.H. Calvert
Institute Cancer Research, Sutton, Surrey; and ICI
Pharmaceuticals PLC, Macclesfield, Cheshire, UK.
A number of more water soluble, less toxic analogues of
N1 -propargyl-5,8-dideazafolic acid (CB 3717) have been
identified as potent inhibitors of cell growth. Many of these
compounds are thought to be metabolised intracellularly to
polyglutamated forms that are well retained by cells.
However, little is known about the mechanism by which
these quinazolines enter cells. We describe here, cross-
resistance studies using two MTX-resistant sublines of the
L1210. The first of these, the L1210:1565 is a reduced folate
transport-deficient mutant which expresses the same level of
dihydrofolate reductase (DHFR) as the wild type. The
second, the L1210:R71 over-produces DHFR by 230 fold.
ICso (PM)
L1210 1565 R71
Methotrexate 0.026 3.6 630
Trimetrexate 0.010 0.034
CB3717 3.4 27.0 10
2-desamino CB3717 0.4 28.0 17
2-desamino-2-methyl CB3717 0.085 53.0 4
It is clear that removal or replacement of the 2-NH2
function of CB 3717 can have a profound effect on the
ability of the molecule to utilise the reduced folate/MTX
carrier, increasing the extent to which these analogues are
able to utilise this pathway. Comparing the results of the
two MTX-resistant lines, we may expect that these
compounds will circumvent resistance resulting from DHFR
amplification, but not that due to deletion of the reduced
folate carrier.
Comparison of two methods for the study of growth and
drug sensitivity of small cell lung cancer cell lines
S. Bicknell, R. Milroy, J.A. Plumb, S. Banham &
S.B. Kaye
CRC Department of Medical Oncology, University of
Glasgow and Department of Respiratory Medicine, Royal
Infirmary, Glasgow, UK.
As part of our studies of drug resistance in small cell lung
cancer we have established 8 cell-lines from patient biopsies.
All grow as floating aggregates in suspension. Estimation of
growth rates and chemosensitivity with such cell lines
presents major problems since disaggregation frequently
leads to loss of cell viability. We have previously reported a
modification of a tetrazolium based chemosensitivity assay
(Br. J. Cancer, 1988, 58, 231) for use with such lines. We
have now compared this assay with the results obtained by
the use of spheroid growth delay technology. Individual
aggregates were plated out in 24-well plates and growth and
response to cytotoxic drugs were monitored by the use of a
television camera linked to a microscope and a computer.
Although a spectrum of volume doubling times was
obtained, this approach was slow and was only reproducible
for those lines which grew as tight aggregates comparable to
man-made spheroids. In contrast, the tetrazolium based
assay was applicable to cell lines with a variety of growth
characteristics giving reproducible estimates of doubling
times (4-7 days) and drug sensitivity (ID50 36-1050nM).
Although both techniques allow study of the intact
aggregate the tetrazolium based assay is more suitable for
laboratory studies of drug resistance in small-cell lung
cancer. However, since the spheroid growth delay technique
allows serial measurements of individual aggregates it can be
used for more detailed studies such as the effect of aggregate
size on the apparent chemosensitivity of a cell line.
Short-term culture of cells from renal cell carcinomas to
determine their chemosensitivity
M.O. Symes, T. Lai, B.R. Stonebridge & P.J.B. Smith
University Departments of Surgery and Computer Science,
Bristol Royal Infirmary, Bristol BS2 8HW, UK.
In 29 cases tumour cells were separated from enzymatically
disaggregated renal cell carcinoma tissue by centrifugation of
the resulting mixed cell suspension, on a continuous density
gradient of Nycodenz (Nycomed AS, Oslo). When the
tumour cell band at the top of the column was examined in
a haemocytometer counting chamber, only carcinoma cells
were seen.
Tumour cells from 29 renal cell carcinomas were exposed
in vitro to increasing concentrations of Medroxyprogesterone
acetate (MPA) or one of several cytotoxic agents for 24
hours. Thereafter the uptake of 75Selenomethionine (75SeM)
over 48 hours was compared to that of tumour cells not
exposed to a drug.
Using drug concentrations of 1 pgml -, MPA produced
>50% inhibition of 75SeM uptake in 5 of 24 cases. The
comparable proportion for Doxorubicin was 4 of 5 and for
Mitozantrone 10 of 18. Methotrexate and Vinblastine were
much less effective. In 3 of 4 cases where >50% inhibition
was obtained with Doxorubicin and in 8 of 10 with
Mitozantrone the carcinoma had spread beyond the kidney.
Thus drug sensitivity may be associated with a high mitotic
rate.
In the 10 cases where 75SeM uptake was inhibited by
Mitozantrone the mean drug concentration giving 50%
inhibition was 0.51+0.18 (s.d.) pgml- . The mean plasma500 THIRTIETH BACR AND FOURTH ACP MEETINGS
concentration time product as measured by HPLC following
i.v. injection of 12mgm-2 Mitrozantrone was 0.3pgml-1
(Alberts et al., Investigational New Drugs, 1985, 3, 101).
This figure was significantly greater when determined using
14C-labelled Mitozantrone, and the ratio of whole marrow
to plasma concentration was 8:1, whilst 15% of the total
administered drug was recovered from body organs after 35
days. Thus reduced uptake of 75SeM following exposure of
tumour cells to 1 pgml 1 of Mitozantrone for 24 hours may
predict clinical responsiveness to this drug.
Reversal of resistance in the breast cancer cell-line
MCF-7/AdrR was most effective with the modulating agent
quinidine
5-FU concentration "ISeM Protein Colony
(pg ml- ) uptake content inhibition
100 47.4+6.0 91.9+ 2.4 100 + 0
10 25.8+7.0 83.4+ 6.2 100 + 0
1 17.3+5.7 49.3+ 18.1 61.0+29.6
0.1 7.8+3.7 6.4+ 6.3 -
Estimation of protein content and of colony inhibition
gave higher values for inhibition than 75SeM uptake. As 5-
FU has a greater effect on DNA than on RNA synthesis,
and as 75SeM uptake measures the latter, it is concluded
that all 3 methods give useful results. In 2 experiments the
effect of mitozantrone was compared by 75SeM uptake and
colony inhibition. Both methods gave similar results at drug
concentrations of 10 and 5pg ml-', but colony inhibition
was greater at 1 and 0.1 pg/ml.
S. Stallard & S.B. Kaye
CRC Department of Medical Oncology, University of
Glasgow, UK.
The resistant breast cancer cell line MCF-7/AdrR provides a
model of drug resistance in vitro. It is also a potential model
to study means of overcoming this resistance. This cell line is
known to overexpress the mdrl gene product, the p-
glycoprotein. Resistance to adriamycin therefore could
potentially be reversed by agents known to interfere with the
putative p-glycoprotein drug efflux system.
In this study five such resistance modifiers have been
compared.
The effectiveness of verapamil, D-verapamil, quinidine,
bepridil and nifedipine at reversing drug resistance in the
MCF-7/AdrR line and the parent MCF-7 line were measured
by the MTT assay.
At a concentration of 6.6pM for each agent, quinidine
increased the sensitivity of the MCF-7/AdrR by 10-fold,
verapamil by 6.8-fold, D-verapamil by 5.7-fold, bepridil by
4.3-fold and nifedipine by 5-fold.
None of the agents influenced the sensitivity of the parent
MCF-7 line. Quinidine was therefore the most effective agent
for reversing drug resistance in the MCF-7/AdrR breast
cancer line. Its modulating activity started at a concentration
of 4pM, and was maximal at 7pM. Those concentrations are
easily achievable clinically, in comparison to other agents,
such as verapamil. Quinidine therefore is an attractive
candidate for further clinical study.
A comparison of (75Se)-selenomethionine (75SeM)
incorporation, protein content and colony inhibition as
methods for measuring the efficacy of anti-cancer drugs
A.P. Moran, T. Lai & M.O. Symes
Department of Surgery, University of Bristol, UK.
The anti-tumour action of 5-fluorouracil (5-FU) on cells from
the colorectal carcinoma line H-29 was assessed in 3 ways.
First the uptake of 75SeM by 105 tumour cells over 48
hours, following exposure to increasing concentrations of
drug for 48 hours was measured. Second the protein content
of 105 tumour cells was measured following 48 hours
exposure to drug. Third following culture with drug for 48
hours 600 tumour cells were plated and the number of
tumour cell colonies formed was counted after 12 days of
culture. Results were expressed as percentage inhibition
compared to tumour cells not exposed to 5-FU. Seven
experiments were performed and the mean +s.d. for tumour
cell inhibition measured by the 3 methods is shown in the
table.
Marked enhancement of base analogue cytotoxicity by
3-aminobenzamide; correlation with increased
phosphoribosylpyrophosphate levels and augmented base
salvage
E. Watson, K. Moses & B.W. Durkacz
Cancer Research Unit, Medical School, University of
Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK.
3-Aminobenzamide (3AB) is presumed to inhibit DNA
excision repair via an inhibition of ADP-ribosyltransferase
(ADPRT) activity. Here we report that 3AB enhances base
analogue cytotoxicity by mechanisms other than an
inhibition of ADPRT or DNA repair.
Coincubation of CHO-KI cells with non-toxic concen-
trations of 3AB (3mM) potentiates the cytotoxicity of 6-
mercaptopurine with a dose enhancement factor (DEF) at
10% survival of 30. Whereas treatment of cells with MP or
3AB alone has no effect on phosphoribosylpyrophosphate
(PRPP) levels, coincubation results in a 30-fold increase
between 0-1.5pM MP, followed by a decline to basal levels
at higher doses (2-10pM MP). Methotrexate (MTX)
enhances MP cytotoxicity by increasing PRPP levels, but the
mechanism is distinct from that of 3AB since MTX alone
increases PRPP levels. We suggest that 3AB enhances MP
cytotoxicity by augmenting salvage via the enzyme
hypoxanthine-guanine phosphoribosyl transferase, for which
PRPP is a rate limiting substrate. 3AB also enhances 5-
fluorouracil (FU) cytotoxicity with a DEF at 10% survival
of 2. 3AB treatment causes a 2-fold increase in levels of FU
in RNA, but has no effect on levels of FU in DNA. This
observation is compatible with increased FU conversion to
FUMP resulting from an increase in PRPP levels. However,
we observe that 3AB inhibits nucleoside transport and we
cannot exclude an inhibition of FUdr efflux by 3AB as a
mechanism of potentiation. The reason for the sharp rise
and fall in PRPP levels in cells treated with MP and 3AB
may reflect fluctuations in levels of MP metabolites, which in
turn alter the flux through purine de novo and salvage
pathways, both of which utilise PRPP. These data
demonstrate novel metabolic effects of 3AB, independent of
ADPRT inhibition.THIRTIETH BACR AND FOURTH ACP MEETINGS 501
The role of anthrapyrazole-iron complexes in hydroxyl
radical formation DNA strand scission and cytotoxicity
M.A. Graham, D.R. Newell, L.H. Patterson,
C. Qualmann, B.K. Sinha & C.E. Myers
Drug Development Section, Institute Cancer Research,
Sutton, Surrey, UK; School of Pharmacy, Leicester
Polytechnic, Leicestershire, UK; and Biochemical
Pharmacology Section, NCI, Bethesda, MD, USA.
The anthrapyrazoles (APZ) are anthraquinoneimines, which
possess certain structural features common to the anthra-
quinone mitozantrone (MZT) and the anthracycline
doxorubicin (DOX). Iron chelation by DOX and MZT is
well characterised and DOX-iron chelates have been shown
to catalyse OH mediated DNA strand breakage. By analogy
with DOX, A-ring hydroxylated APZs might also chelate
iron. Hence, this study investigates the relationship between
iron binding, OH radical formation, DNA strand scission
and cytotoxicity with four APZs which differ in the A-ring
hydroxyl substitution. In vitro cytotoxicity tests against a
CCRF-CEM cell line, ranked the four analogues in order
of potency with IC50 values of, 7-OH (CI-941)
(8 x 10 -9M) >10-OH and 7, 10 unsub.(2x 10 -7M) >7, 10-OH
(1 X 10-6M). The latter result is probably an under estimate
due to the chemical instability of the 7, 10-OH APZ which
has a tendancy to form an A-ring quinone. Fe(III) binding
(as measured by difference vis-spectroscopy) showed that the
7, 10-OH and 10-OH APZ readily chelated iron with an
optimal drug:Fe ratio of 1:2. In contrast, the 7-OH and the
7, 10 unsub. APZ produced relatively weak or no spectral
changes. Using ESR spectroscopy, a H202 dependent
DMPO spin adduct characteristic of OH was observed in the
presence of the 7, 10-OH and 10-OH APZ, but not with 7-
OH APZ or the 7, 10 unsub. APZ. These results indicate the
importance of the 10-OH group in iron binding and
subsequent OH formation. The ability of the APZ-FE
chelates to induce DNA strand breaks was studied using
pBR322 plasmid DNA in the presence of glutathione as a
source of reducing agent. Following a 30min exposure of
DNA at 37°C to the APZ-Fe mixtures (1:2), single strand
(SS) and double (DS) breaks in DNA were separated and
quantitated using agarose gel electrophoresis. All the APZ/
iron mixtures induced SS breaks (30-50% total DNA) at
concs>5 UM drug, although the effect was no more marked
than with iron alone. However, in contrast to iron alone, the
simultaneous presence of the APZ and iron resulted in total
loss of the supercoiled DNA, indicative of multiple DS
breakage, Hence the DNA binding nature of the APZs may
facilitate Fe mediated free radical DNA strand scission. The
lack of correlation between iron binding/OH radical
formation, plasmid DNA strand scission and cytotoxicity
indicate that, for CI-941, cytotoxicity is unlikely to be
related to the formation of an Fe complex and subsequent
OH radical mediated DNA damage.
Synthesis and some biological properties of quinazoline
antifolates variously substituted with fluorine on the benzoyl
ring
T.J. Thornton, A.L. Jackman, B. O'Connor, J. Bishop,
L. Hughes & A.H. Calvert
Drug Development Section, Institute of Cancer Research,
Sutton, Surrey; and ICI Pharmaceuticals, Macclesfield,
Cheshire, UK.
Previous studies of the effects of benzoyl ring modifications
to N"°-propargyl-5, 8-dideazafolic acid (CB3717) have
included the introduction of 2'-and 3'-Cl and 3', 5' di Cl
substituents (Jones et al., J. Med. Chem., 1986, 29, 468). 2'-
Cl substitution slightly reduced thymidylate synthase (TS)
inhibition, whilst 3'-substitution markedly reduced TS
inhibition. Both analogues were less cytotoxic to L1210 cells
than CB 3717. The present study concerns the effect of
introducing another halogen substituent, fluorine into the
benzoyl ring of the 2-desamino-2-methyl analogue of CB
3717 (Proc. Am. Assoc. Cancer Res., 1988, 29, 1137).
Inhibitory effects on isolated L1210 TS and L1210 cells in
culture are tabulated. The key step in the preparation of
these compounds is the synthesis of the various 4-nitro- or
protected 4-aminobenzoic acids appropriately substituted
with fluorine.
Benzoyl ring L 1210 TS L 1210 Cells
2' 3' 5' 6' IC50 (/1M) IC50 (PM)
H H H H 0.04 0.085
F H H H 0.02 0.027
H F H H 1.24 0.051
F H F H 0.60 0.027
F H H F 0.08 0.061
F F H H 1.71 0.28
2'-Monofluoro substitution improves TS inhibition and
L1210 cytotoxicity, 3'-Monofluoro substitution reduces TS
inhibition by 31-fold, but slightly improves cytotoxicity.
Introducing a second F into the ring progressively worsened
TS inhibition going from 2',6' diF to 2',5' diF to 2',3' diF
although these compounds retained the same level of cyto-
toxicity. The beneficial influence of the 2'-fluoro-substituent
may be due to an interaction between F and the amide H, as
evidenced by 1H-NMR spectroscopy, causing co-planarity
between the benzene ring and the amide residue.
The synthesis and thymidylate synthase (TS) inhibitory
activity of the poly-7-glutamyl derivatives of some analogues
of N'0-propargyl-5, 8-dideazafolate (CB3717)
G. Bisset, K. Pawelczak, A.L. Jackman, E.E. Dix Perkin,
A.H. Calvert & L.R. Hughes
Institute Cancer Research, Sutton, Surrey; and ICI
Pharmaceuticals, Alderley Park, Cheshire, UK.
CB3717 has been shown to be metabolised intracellularly to
poly-y-glutamate derivatives by the enzyme folypoly-
glutamate synthetase (FPGS). These metabolites are very
much more potent inhibitors of isolated L1210 TS (up to
- 150-fold) and are preferentially retained within L1210 cells
(Sikora et al., Biochem. Pharmacol., 1988, 37, 4047).
Polyglutamation of folate-based TS inhibitors may therefore
enhance their cytotoxicity. The more water-soluble 2-
desamino (A) and 2-desamino-2-CH3 CB3717 (B) analogues
were found to be less active against TS (8 and 2-fold
respectively) but significantly more cytotoxic to L1210 cells
(10 and 40-fold) (Proc. Am. Assoc. Cancer Res., 1987, 28,
1073; 1988, 29, 1138). Both these analogues were found to be
substrates for FPGS. We have synthesised some of the poly-
y-glutamyl derivatives of (A) and. (B). The poly-y-glutamyl
derivatives of B with a chain length of up to 5 glutamates
were synthesised from 2-desamino-2-CH3-N'°-propargyl-
5,8-dideazapteroic acid. The tri and tetraglutamates of A
were synthesised from 2-desamino-N' 0-propargyl-5,8-
dideazapteroic acid that had been obtained by carboxy-
peptidase G2 cleavage of A. The TS inhibitory activity of
these polyglutamates are shown below.502 THIRTIETH BACR AND FOURTH ACP MEETINGS
Compound TS Kiapp+s.e. (nM), Fold increase in TS inhibition
A 63.68+2.89
A+glu2 0.97+0.06 x66
A+glu3 0.63+0.07 x 101
B 31.18+1.92 -
B+gIul 1.11+1.92 x28
B+glu2 0.40+0.03 x 78
B+glu3 0.27+0.03 x 115
B+glu4 0.40+0.03 x 78
The fold increase in TS inhibitory activity per glutamate
addition is similar to that previously reported for CB3717.
The remarkable increase in the cytotoxicity of A and B over
CB3717 is therefore probably due to an increased rate of the
intracellular synthesis of polyglutamate metabolites.
Direct evidence that a free radical mechanism is involved in
adriamycin toxicity
A. Bartoszek, L. McLellan, J.D. Hayes & C.R. Wolf
after 24h treatment of 105 exponentially growing cells with
anthraquinones (0.01-10pM) and a subsequent 48h drug-free
incubation. To measure drug uptake MCF-7 cells were
incubated with the anthraquinones (15 M) for between 1
and 90min, the cells were then centrifuged at 12,000g and
the supernatant analysed by HPLC using a C6 (Spherisorb)
15cm column with a acentonitrile (30%): ammonium
formate (70%, 0.5M, pH 4.25) mobile phase. All the anthra-
quinones were cytotoxic to MCF-7 cells with ED50 values as
follows: 1,5-AQ (<0.OlMM)>1-AQ (0.01Mm)>doxorubicin
(0.04yM)>1,8-AQ (1Mm)>1,4-AQ (2yM). The wide range
of cytotoxicity observed was not due to differences in
cellular uptake which for all compounds appeared to
approach steady state after 60 min with the following uptake
values: 1-AQ (34%), 1,8-AQ (34%), 1,4-AQ (36%), 1,5-AQ
(46%), doxorubicin (47%). The ranking of cytotoxicity does
not correlate with DNA binding affinity which is 1,5-
AQ> 1,4-AQ> 1,8-AQ> I-AQ. It is likely therefore that
other mechanisms contribute to the cytotoxicity observed. In
this respect these compounds have been shown previously to
generate reactive oxygen species.
ICRF, Lab. of Mol. Pharmacol. Hugh Robson Bldg, George
Sq, Edinburgh; and Dept of Clinical Chemistry, Royal
Infirmary of Edinburgh, Edinburgh, UK.
A variety of mechanisms have been proposed for the cyto-
toxic effects of adriamycin (Adr). However, most of the
evidence for these pathways is circumstantial. In this study
we have obtained evidence that a free radical mechanism is
directly involved in the cytotoxic effects of this compound.
Adr can be converted to free radical products by cytochrome
P-450 reductase. The MTT assay was used to generate
cytotoxicity curves for Adr towards the MCF7 cell line in
the presence or absence of the reductase. The presence of
this enzyme together with the required cofactor NADPH
significantly increased the cytotoxicity of this compound. A
5-fold increase in the cytotoxicity being observed. This effect
was dependent on both the dose of Adr and the amount of
enzyme added. If the reductase was preincubated with Adr
prior to addition to the assay no change in cytotoxicity was
seen indicating the involvement of an unstable toxic reactive
intermediate in the reaction pathway. In addition, initial
studies indicate that the addition of purified glutathione
transferases to the MTT Assay in the presence of NADPH
and the reductase can reduce the cytotoxicity of this
compound.
Uptake, DNA binding and cytotoxicity of
diethylaminoalkylaminoanthraquinones in MCF-7 human
breast cancer cells
J.E. Maine, D. Cairns, J.R. Brown & L.H. Patterson
Dept of Pharmacy, Leicester Polytechnic, Leicester LEJ
9BH, UK; and Dept of Pharmaceutical Chemistry,
Sunderland Polytechnic, Sunderland SR2 7EE, UK.
The importance of the DNA binding anthraquinones as
antitumour agents is exemplified by the clinical use of
doxorubicin and mitozantrone. However, doxorubicin
therapy is compromised by a cumulative dose related cardio-
toxicity while mitozantrone is indicated only for treatment of
advanced breast cancer and acute leukaemias. This has led
us to investigate the cytotoxic potential of other DNA-
binding anthraquinones of which the 1-, 1,4-, 1,5- and 1,8-
diethylaminoethylamino-substituted anthraquinones are
described here. The synthesis and DNA binding affinity of
these compounds has been previously described (Islam et al.,
J. Med. Chem., 1985, 28, 857). Cytotoxicity was measured
Increased anabolism of 5-fluorouracil in Walker
carcinosarcoma following methotrexate pretreatment, detected
by 19F MRS
P. McSheehy, M. Prior & J. Griffiths
CRC Biomedical Magnetic Resonance Research Group,
St George's Hospital Medical School, London SW17 ORE,
UK.
19F magnetic resonance spectroscopy (MRS) can follow
tumour 5-fluorouracil (5FU) metabolism to cytotoxic fluoro-
nucleotides (FNuct) non-invasively in situ (Stevens et al., Br.
J. Cancer, 1984, 50, 113), and we have shown in the Walker
carcinosarcoma that the FNuct peak area is related to
growth inhibition. 5FU 3 hours after methotrexate (MTX-
SFU) gives a superior therapeutic ratio in the Walker
tumour compared to both drugs simultaneously, alone or in
reverse order (SFU-MTX) (Wayss et al., Med. Oncol.
Tumour Pharmacother., 1985, 2, 27). Our aim was to use
MRS to detect increased SFU metabolism to FNuct
following the MTX-5FU schedule and to relate this to
cytotoxicity.
For MRS, 6 anaesthetised rats bearing Walker tumours
received SFU (50mgkg- i.v.) 3 hours after MTX
50mgkg-1 (test) or 0.9% NaCl (control) i.p. After 60min
the experiment was terminated by excising and freeze-
clamping the tumour for analysis by ion-exchange HPLC.
For growth studies 10 rats per group received Walker cells
on day 0 and on days 1 and 5 received either 0.9% NaCl,
SFU (50mgkg-1), MTX-SFU (50mgkg-1) or SFU/MTX
(50mgkg-1) i.p. Tumour size was assessed on day 8. Results
are mean+SEM.
After 60min the 19F MRS FNuct/SFU peak area ratio in
tests was significantly increased: 0.68+0.24 vs 3.17+0.97
(P=3.1%). The SFU peak area was unchanged (866+120 vs
1022+245) while FNuct was significantly increased (568+217
vs 1949+420), P= 1.5%. HPLC showed 50% of the FNuct
in both treatments was FUTP, which was increased 3-fold in
tests. MTX-SFU reduced tumour growth (P=1%), whereas
SFU alone did not, but it was not significantly different to
SFU-MTX. MRS may have a role in optimising the
scheduling of MTX and SFU combination chemotherapy.THIRTIETH BACR AND FOURTH ACP MEETINGS 503
The effect of cationic DNA affinity binders on the DNA
sequence selective alkylation of guanine-N7 positions by
nitrogen mustards
J.A. Hartley, S.M. Forrow & R.L. Souhami
Dept of Oncology, University College and Middlesex School
of Medicine, 91 Riding House Street, London WIP 8BT,
UK.
Large variations in alkylation intensities exist among
guanines in a DNA sequence following treatment with
chemotherapeutic alkylating agents such as nitrogen
mustards and chloroethylnitrosoureas. The majority of
compounds react preferentially in runs of guanines which
correlates well with the molecular electrostatic potential at
the guanine-N7 position imposed by the nearest neighbour
base pairs, and suggests that the specific biological effects of
such compounds may depend on preferential reaction at GC-
rich genomic locations. It is also clear that the substituent
attached to the reactive group could impose a distinct
sequence preference for reaction.
In order to understand further the structural and
electrostatic factors which determine the sequence selectivity
of alkylation reactions, the effect of increased ionic strength,
the intercalator ethidium bromide, AT-specific minor groove
binders netropsin and distamycin A, and the polyamine
spermine on guanine-N7 alkylation was investigated using a
modification of the guanine-specific chemical cleavage
technique for DNA sequencing. Increased ionic strength
produced the expected reduction in reaction rates but did
not alter the rank order of reactivity of guanines to nitrogen
mustards, although the degree of selectivity was altered in
some cases depending on the charge on the mustard
molecule. Alkylation was also dose-dependently inhibited by
all the cationic DNA affinity binders studied. More
interestingly, however, the guanine-N7 alkylation pattern
was qualitatively altered by pretreatment with ethidium
bromide, netropsin and distamycin A. The result differed
both with the nitrogen mustard and the cationic agent used.
The effect was most striking in the case of netropsin and
distamycin A indicating that selective binding to AT
sequences in the minor groove can have long range effects on
the alkylation of DNA in the major groove.
Enhanced 4-hydroperoxycyclophosphamide cytotoxicity and
DNA cross-linking following BCy NU-mediated glutathione
depletion in human leukaemia cells
C.M. Chresta, T.R. Crook & R.L. Souhami
Dept of Oncol., Univ. College & Middlesex School of
Medicine, 91 Riding House Street, London WIP 8BT, UK.
N,N'bis (trans-4-hydroxycyclohexyl) N'-nitrosourea (BCyNU)
is a nitrosourea which has carbamoylating but not alkylating
activity. It has been demonstrated to carbamoylate and
inactivate glutathione reductase thereby reducing the intra-
cellular levels of glutathione (GSH). We have previously
shown that buthionine-S,R-sulphoximine -mediated GSH
depletion potentiated the cytotoxicity of cyclophosphamide,
with a corresponding increase in DNA cross-linking. We
have, therefore, investigated the potential interaction
between BCyNU and cyclophosphamide. Treatment of K562
human leukaemia cells with 15gM BCyNU for one hour
resulted in depletion of glutathione to 40% of control values,
without significant reduction of cell viability as measured by
the MTT assay. Subsequent treatment with 1OgM 4-
hydroperoxycyclophosphamide (4-HC), a self-activating
derivative of cyclophosphamide, reduced the level of
glutathione to less than 20% of control values. BCyNU
pretreatment enhanced the cytotoxicity of 4-HC resulting in
a dose modification factor of 2.5. Alkaline elution analysis
of cellular DNA demonstrated that the level of interstrand
cross-linking was 2-fold higher in GSH depleted cells than in
non-depleted cells, in addition the induction of single strand
breaks was markedly increased.
These findings demonstrate that BCyNU potentiates the
cytotoxicity of 4-HC, and suggest that this is due to the
increased formation of DNA interstrand cross-links caused
by a reduced intracellular conjugation of drug with gluta-
thione which results in an increased binding of drug to DNA
targets.
Photosensitisation of human leukaemic cells by
anthracenedione antitumour agents
J.A. Hartley, S.M. Forrow, R.L. Souhami, K. Reszka &
J.W. Lown
Dept of Oncology, University College & Middlesex School
of Medicine, London; and Dept of Chemistry, University of
Alberta, Edmonton, Alberta, Canada.
While 1,4-diaminosubstituted anthraquinone antitumour
agents such as mitoxantrone and ametantrone do not show
marked photosensitising capabilities, the structurally related
1,5- and 1,8-diaminosubstituted compounds (AM1 and
AM2) efficiently oxidised NADH upon illumination (A>475
nm). Illumination of aerated samples of AM1 and AM2 in
the presence of NADH has previously been shown to cause
oxygen consumption, formation of superoxide radical and
hydrogen peroxide. Similarly these compounds caused
formation of DNA single-strand breaks (SSBs) upon
exposure to visible light and a correlation was established
between extent of DNA damage, oxygen consumption and
NADH oxidation.
In the present study AM1 and AM2 were tested for th'eir
ability to photosensitise human leukaemic cells in culture.
Viability was assessed using the MTT assay and DNA SSBs
by alkaline elution. Following a 1 hour exposure to AM2, an
ID50 value of 53pM was obtained in the dark, which was
reduced to approximately 2pM following illumination for
2min, a dose of light which was non-toxic to cells in the
absence of drug. A shift in cell viability curve was also
observed for AMI but under identical conditions the dose
modification was only 10. In contrast,'neither ametantrone
or mitoxantrone gave a decreased viability upon illumin-
ation. No DNA SSBs were detected in unilluminated cells up
to 10,UM drug, and were only seen at the ID50 (50,M). In
contrast, a large amount of SSBs was observed at 2pM AM2
following illumination, although light alone produced no
damage. Whether such photochemical reactions will
contribute to unnecessary phototoxic side-effects, or can be
exploited in photodynamic therapy remains to be
established.
A new tumour-associated antigen which is recognised by
monoclonal antibody NCRC-37 and expressed on the cells
and in the sera of gastrointestinal cancer patients
L.G. Durrant, E. Jacobs, R. Charnley & R.W. Baldwin
Cancer Research Campaign Laboratories, University of
Nottingham; and Department of Surgery, University
Hospital, Nottingham, UK.
A monoclonal antibody recognising a tumour associated
antigen on gastrointestinal cells was produced from fusion of
splenocytes from a mouse immunised consecutively with four504 THIRTIETH BACR AND FOURTH ACP MEETINGS
different colorectal cell lines. The antigen is present in the
acini of gastrointestinal epithelial but is expressed by the
cells and in the pseudoacini of gastrointestinal tumours. It is
not expressed by haematopoietic cells or on lung, kidney,
liver, brain, heart, spleen, testicular or skin tissues.
The epitope is expressed on a high molecular weight
(>200kDa) glycoprotein and may also be expressed on
other antigens (experiments in progress). It is not found on
carcinoembryonic antigen. However the epitope is found on
an antigen(s) secreted into the sera of patients with gastro-
intestinal cancer.
Percentage of samples with following
(antigen(s) (units ml-1)
0-10 11-20 21-30 31-130
Colorectal cancer
Normal 60 24 16 0
Primary tumours 27 32 14 27
Recurrent tumours 0 33 0 67
Metastases 7 7 13 73
Gastric cancer
Normal 0 33 67 0
Gastric tumours 6 6 54 34
There was no correlation between the antigens detected by
antibody NCRC-37 and CEA or CA19-9 antigens.
NCRC-37 detects a new tumour associated antigen which
may complement postoperative CEA monitoring for
detection of recurrent disease or response to therapy.
Development of an ELISA to detect early local relapse of
colorectal cancer
L.G. Durrant, N.C. Armitage & R.W. Baldwin
Cancer Research Campaign Laboratories and Department of
Surgery, University Hospital, Nottingham, UK.
There is considerable interest in non-invasive techniques for
identification of patients with recurrent disease following
resection of primary colorectal tumours. At present CEA is
used in postoperative monitoring, but computerised tomo-
graphy showed identifiable recurrence 7.5 months before an
increase in CEA was seen. There is a need for indentification
of a new tumour associated antigen secreted by a large
percentage of early recurrent tumours to complement CEA
monitoring of this disease.
The Y haptenic blood group is expressed by the cells of
malignant gastrointestinal tumours and therefore assays to
detect serum antigens bearing this hapten have been
developed. The specificity of the assays was between 88-93%
and the sensitivity in detecting extensive disease was between
24 and 33%. However, up to 67% of patients with local or
abdominal recurrent disease secreted antigens expressing the
Y hapten whereas only 30% of patients with overt hepatic
metastases secrete a similar antigen. There was no
correlation with expression of CEA or CA19-9 antigens.
Recognition of antigens bearing the Y hapten may be useful
in detecting early local relapse of colorectal cancer.
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